var title_f5_36_5696="Ascaris lumbricoides Endosc";
var content_f5_36_5696=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Biliary ascariasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An adult Ascaris lumbricoides worm protruding from the major papilla is grasped with a forceps during endoscopic retrograde cholangiopancreatography.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of D Nageshwar Reddy, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_36_5696=[""].join("\n");
var outline_f5_36_5696=null;
var title_f5_36_5697="Laryngeal mask airway";
var content_f5_36_5697=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laryngeal mask airway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 274px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAESAXYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDM1hD/AGxGSCVRBj616x8PJTJp0f8As5Feb6qg+2g46qK7z4c3Gy2lQno2RThuVLY7HVY2mkjUklQeRWH8Rx89ljtHW7LMZSu3jnFc98RJRH/Z25XYFMEqu7HucdqtrQhMxdEtJLmVUQZ3Gu9t7/TdJgZJr22iaLAcPKFIJ6Zz0zWV4TWzhtTKs8Zkb5QOhBPsa+fP2mrLUNPurJlluTpGoO7M2Rh5kIG1voCcfWhWimnuEuZ6x2PUvEWqRajrEj288UygceXIGx+Rrs/h/wDLYu/sa+DNHeeK/i+yXEtrOXAWRGKsPTp2r65/Z/8AGbeI/BOpfa8f2hpx8uZh0kBB2t+hzURbuNvSxLEn23xZqFwwyqPgfWtLX4pW0wW8QIac7WPotangPTIzaTahMu955iQD6CovGWpW1tFGjSqrxvu2r8zH8BQ7JXZSbbsjhtR03Zd7JsJsjIVB2AFYFzc21ovm3EiRrtILMevoBUfi3xVPNeySWUQTI2h5OT+Qrz28eSecS3MjSsDn5j0+npXDOsr2idCpSteR2smrSyQtHbLhXI+cjnFNje7DMPPIj9MZJ/Gi3jAijIXGVBpXkjj5kdV+pxXFWxz+GC+YKn1ZqeJD9n+Fd3KeDLLjP4//AFq8j+D1ibvxjHOQCsXqO5r1L4o3At/hLpyKf9e5YY78E/1rj/gDaFtZmdhxlT+hP+FejS0pR9Ec8tZM9X8cT2lnPaW5ijSZ4i2UAyepyTXmeu/v7vR4OplvQxA9EBb+grofijqCx+MIpASYo5Vt2+b7uE5wPxNYvlef4sgVRlbW1aQ47M52j9Aa83Et+15vJ/1+RpD4bGmsK85PNW7YSRnMbtnP8PFCxdz+JNSF1UAJ94d656NGdT4S5SS3NBLiYJln3gf3hzW3onhy91+yu5rdIUe3uDAY2bBb5VYEH3DCuODS7+JG56g812Wg+L7jSrbU0+zI0t6/mCRDt8t/LVAQPTCg/WvSpRq0/id0YyknsjBvNGuY2fMEjBeSyruGMlc5HbIIz7ViXFvtdT6MK9o8J+ItFL3BF0LZ5CkMUUw27YkXaoJ6ZJ3Mfc1Z8caXptz4Y1K8W1tZJkgZ45kUZBHfIrphWTkkzCv/AApej/I8Uif0HOcVOnDfSq6jZjjjHNTxjPzDsK9M+HZza2lrpXjolNQjkuNStt72yIx2EdMueC3Gce9dDJkkgDtzXIeOlXT9U0XVl4aG4CyH/ZP+TXXghpCynKkDFTHS6O7GvnUKvdfih0Me0bucVVvwdhUDir4bKoD0JouoQQhH3c7apnGpWZ6L8D18nwxeSvlwLwlUHdtowK7XxDMYLcNcNmduqj7q+wrkvgoPJsdTi2s22dXUdslcf0rS8b32zdub5wOi9BXFU0kz73LHz4am/I47WpxIzYJz39hXMXrbzlf/ANVT3N/vbfIdqc9eM1mfafPZwnQVkehsyndZyQpxWJeQYjJbk54roba3a4dxnpyTVbUbTEROOnaplsO5wGooVk+XGM81HpUhS4I7EVa1qPDjHHPT0rOtm8m5U+hpU3aSOLHU/a0pQOmhcNgetXBHgdMCqCMitgcgVZW9KgKFLA16R8EyQnHA65pG55PSoXlkZspE5/Cm7Lxvuwt+NAkmOOM1GxAPFKbW8bqqr9WpPsFwT800S/TmkVZdyNmGcdKidgasHTzn5rjP0FH2CLq0kjfpQ7jTSKJbB4NFW2tLdf4GP1aikXzRPUNV5lRvat3wbdeS8q+oFYd8N8KkdRRpNx5EoOSAetYJ2Z9pLY9UsL3cwz0zWvqqRyJayFAzqvH59K4nQ2nupN0Skxjq54UfjXXXt59l04vgPIBtTNTWrqCstyqNBzd3sYXiLxDa+G9Ie8v7omXcRDHIw4PoPWvPb3xXpniv4cXHhjXFjGoK5KNLw2SdysjdmAOCK8q1yPXH8cWF34yne5aa7eOGNX/dKocq2Oy49Ppmud8bade6JqssbuxtjvYTrnZIOwPoemQelTCnUtzt6hWr021TirfqGteBbixnKW+oRywqRywKlSe1e0fA7TJtB+HPiW/lO6e9dI4z03BQVHHpk187walfXQW2FxK0sirBGg5UgnBz789a+kfDPiLwzpuj6PoMet2Ahg2eazS4G5OTnPcsafM4q8jKnFuSTZ6DBJcafolvZvOx8tMME+UE964fxA7OrcgDOcCuquNUtL6PdYXdtcg94ZVf+RrlNXQkN2PvXDOTlqerCKWx57qnzOwxiqMdp9ot9RlIwtvbFz9SyqP1atrUbcqTkdfSmWEY/wCEe19+hc2sI/4FMCf/AEGs6Xxq4VtINki27v8AfmkYDjG7GPyp8drDHlkjUMfxJ/OrTJvclQR6kVcsrWKSeJbqR4YWYB2VckD1A7153K2YXRlfHiQweEfDloSAPKLEfgoq/wDBS0gtIDeSYWIAMzYz2A/pWR+0mLZb/SLb7YuyO24UISx59PwqX4AGbWvGGk6bN5gtPKaSZFbClFQnB9845r6FR0RwyaJrTww3ibxNqWoa0ZobKOaRosLtJZjkYz14xk1oRaLZaLfXF1HdzzmRVU+coB+Xp0r2LV/C1gsjrDczWpHCi4TKkexHQVx2teBbwfvQryR4yHgbepH061Eop6WHaS1Zwd3qLsf3SjaD1PTFRJfhyRJER7jmtO70WaBmBj34/ujB/EVz+uJLaWTyA+TISEEki5CEnGePSkk07CNKGWORvkfn0pl5rVlZ4E1wucZAA6/0ryfUPEWpWOpyRzXKXQjO0PG+AfcY7fWqd34mmYv9lUK0igM78kfQdPxq+R9RHsFn4k02YhWuFhY4AEvGfoa2zcTLBJDbzSIsg2sisQGHoRXz74ftZb7VoHuEeVFbJycdOlevabPcNeQB3IBcd+lRa00tzOtf2UvR/kbQAmgWReODxTrT/jyyR3AJp0KeXIQowrrv2+hNSmPaojjBKsMHHY16p8Qc74zsF1HQb2MgmRYy8f8AvLyP5Gl8I3v2/wAPWU4OWEYRv95eK6KPT5pYgoU78H865L4fW72Gs67oUxRTBILiPJwNremfqKnZndH95hWusXf5M6UKS4wTViPkYbp1NWXWzgX97cKT6LzTbe7tpriKC2heWWVxGnuScCnc41Ft2R6j8J7V7Xw/fXkgIWebCZ77RjP5msDxzco8jl3wOflHFd9rRi0PQLe0hAVYowvHTOOT+dfP/jrVJZrhwjcN3rgrT95n6JgKDo0Yw7I5jUtUefVWQHESDaAO1TTamlpB5m4BFXnnrXP3B8sF85c96zLiee7uI7aKSNFDAsz9PasEzr5G2ex+CbSSXR2vLr5BKdyhuMDtTdUEW5gvzD1Ap/hbSLhbFXa5jvGIyTIc8+1Wr2GSFv8ASIkRfarexMYnm+v2bFnYLx9K4+4zG+T1Br13VbaN4iU2uCO1eXatEItQlQj5c9M1C3JqLQ6rS7iKXT4JFjjztAPHpVzzwoydoPoAK5jRZfKtggOcEkVrxuz4IHPqa9KDvFH59iqahWml3ZdWcltz59hSNPnvVUq3BJGKeF+XJOaZg0SMxPNRuRxSDb68etKwGeOpoFsRllBx3qN2yCBUhAzzTRgc+tA0R4z160VJgfWigdj1aLRtQuYwsNtI3PU8Ct3Q/A0nnLNqcgEY58pDyfqa7kxxxmOGMDbkAVqQQgpgjFeS609j9I9hBO5xmtXo0yJUihCW8Y6KvAry/wCKXjO8Ohk2EmI96qGXqzZBCj8ASa9q8RaYJYGBHymvFvG/hR0t5rayGTKScnnZnqVHriuez5rs6YtWOR+MAjt9dupVufMiY21+kfaBptrOB9Tk15fceLb8rNA7+ZEWON3IPpkHrx3/ADzXQfEFxC+oWMbs7tLHs3k7tiqMdew6V56YZSoby2KnODj869WEm9UeJVpJu0kXYbuW41SAxqEJlTaqDHORiutj+GnijWLu7uLayiSIzPzJMqgHPI61z/hG0juNbslZmEyTq+CMABeefcnAr6ctphZaXDAvDBcsfUnkn8zWdWpyao3oUFNa7Hg4+Fni20fdB9nWQdDFdAGra6v478IqBrFtcXViOD9oHmLj2kGSPzr18X5luNqA8VakZpFKbMqeoPINczr83xI6lQ5fhbRwNjrVn4g04XVk2DgeZET80Z9D/jTYMtpl3bIfmlu7X9HY1h+OdGfwpqy69o8ey1kbbdW68Lz3A9D+hrpPCskV5crJCQ8cpjkQ+vNZ8vLJSWzCcnKDjLdG/HaPGR0Pptq5ZW6tNEHAHzjO761FquqWulQtNczRQRZwWdsLn0rz+/8AHV3f3og8N28srZ/4+CmFH+6Dx+J/KphRcnojmlNJC/HqSS4+KFjBBEZjbxQkKOcjOa9J0rSZfC9hq+v2ywW921usVvdwyAoC7jd09h3xXjENtc2fiQaprKrqNyGy8Usr4bIxjeMHPPBHT0r17wxbRa74L1A6PZ6hLb/bUjura4K3HlhYyQFIwWXLDkjIxXoTslzNbdjL69UoUJ01rF76Xenbrf0N7wt8T9QvdKt59VNncJKzqpb93vwSBtPvjOK7XTPHGlXLKkzy2rHjbKMr/wB9CvA/Fvha/wBRstLh0qzC6dYXWZwgKeUuR/Ceema6KdQ6kMMqeKUOWavF/wBeZz0qqqQUlsz3GaDTtWi3FLe6Q/xLgn8xzXM674E07UrWWBSyJICCjjev+NeY2093pyF9PupImHTJLH885rT8K/EfxF9mP9tWkTSKxXa3BI7HIos0XzI4zxV8BLuKVptMuS8Z5wPn/wDr1zNl8KbxLgpLIhdOqt8pP0Br6PsPHWl3WFuvMtJD/fGV/MVryix1OHcBBdIe4w1Dk3uUj56t/C50iJmnRbeNBuZn44Hck9qpaH4l0S81qCzjuSH84Krsh2tz2Ne9X/h+3mheGKSSOJhgxP8AOn5GuEvvh3ptldNqC6XAbiPlZoDtCn1KdPxFKEVzJmddv2UvR/kMur7TopAyLJKdoUYGASKiGrsVItLJBjn5uTUv9m5jLBfutwD796uw6ftAIGCK9Gx8OZDXmqXDlfNCDGcIMVieIdHNpqej6ylreSSThre7uchIlAPygDGWOCMnPbFd5FaBQzbQGatzxFb/ANs/CK7twB5+lzEqR12nn/Gk46Ho5alKcoPqmcJDpakgEfMfu5rr/h5ocUniaCWRR5dsDMfQEdP1rgtH1ZrmCzndslcBgPUHB/rXuPgGx8rRru+BCPOdiMRn5R3/ADpSdo3OvB4F/WoJ7b/d/SIfH175sRRCrp6qc4+tfPfia4zOwHPODXqXjXVGNzLE5EcnKiWPv9a8P1O7Ms8gfAkB5x0b3H+FebUdz7dLlViGBIri9iW5JEIOX55I9BXrHh2LTNQljkS1t5oUjIKmMED5eAa8WV4LmdkkmkjKjqv1rpvCFrdW+pi5gvZTZRjL/wAPPYe/0qKVWUG0uo8VllOsqdVyalF38n5HYeFra4XVLtYbqWK1DkJGuNq/Suq1KCSO1lea7adyMoGUYHqDisLw95sDtvsJGVmJEgxj6kVc1+dre1aTdhSMFR2p9C3HU4nVb4Qzk2+Uzw8Z7GuG8RShtQZgPvAHrWvrGoq14WPRRj61xOq6mXmkaHljwD6CnTgcWIqqLsbNrdtEoGeK0ItQJH3q57TLn7Xagt/rU+Vv8auKOfeuxNpWPkcRTUqknJa3N+O93Y5qwlx/tVz6EjHNTpKcYPNWpHFKiuhtCfPU1Ks2TzWQshPepFc9s00zJwNMyD1xTC+T1quhJwDUu2hsmw8yUU00U9RXPqJNRzdBT1XaQa6iG5RlyGHPpXA6VeLJcGP/AJbIcjcOorrYpwyKJEHT7yivHlex+mSakXL+4RIJA5GFTOWPXNckFtZ50BKsrHufun0ro70Ry2hBVWXHf0rz7xDcS2m2bT1icKfmjJxn3B9ah7lRtaxH42+Heh606y3lpG7AEB8YI/EV4R8RPh7faVdxWunrJNpJAaMphmQ9we57V7/b+IIruBDKzwuPvo/+NcZ8T5/PsUaxlDEnHysKvnnFe6ROEKmkjx/StLkstVjkSMid5EVEyCQBgDOO/GTXscsUkmAcgHrXM/DzQprzVZbmeJxDbbNsh6NIx6flmvRL+0ETHPFEoytzS6kwkvhXQxraFISSo59asM4ROOtQy5U4HSq1zKec5rJmyMrxGkd9ZT2twA0UylG/HvXmPhDWLvQ7bUbOK2+1XlpJ5aITgYJ6/QEfrXouoSnBGeK86kAtfH6EcR30RBz/AHsf4gVpQ1bj8znxSsuZE8lhe6zcrdeILjz5F+5AvEcY9hW/p9vFBgIqqo7Ck24JHFOVyoPNdkTzWQNo1n4iuZdPj8SWuj6ux3RJdnbFKvYeYfuknOK6n4d67rHwes7vSfE3h+e6tLmf7WL6wmWU4IC52jqPlznIryPXWRfEbSvHHMQgPlyDIIxVG1ur1Lqd4Lw2sGxnVN5K8chB15NatXWpCdj6+0bxv4L8ap5dtqFpLcOMGC5/czfTnBP4E0uqeCLVoLgafJ5MsiYQTguEPYgjn8818cancSS2cFzf2yeZOC0ci/KWwcE/mK2/C3xP8V+GQi6dq801qv8Ay7Xf76PHpzyPwIqHB7LUrRnqqeH/AB1pWpW9rrWm291ZyOVa/tWyiDsWx0/ECszUtchsvFn/AAj8kHm3BH/HxFICoOCfxHvWz4Y/aIspykXiXS5bRzwZ7M70+pQ8j8Ca9AtbvwZ43Zbmxk06/ulHDphJ0z+TUc1nrog5TzRmKjn9KSC7uLeXdaTSRSeqMVNbvxI0zT/Cej/2kLiYo0oiWBwCScE/e9ABXk2n+MBrF7DZLE8AnbYSnzP/APq9+1U2hWPWLTx5qlo4W4C3kX/TQbX/ADFbL+PtM1C3jtik0dzdSrbpGRkFmPPI9Bkn6V5NdK8SlIXZrfaVAJ5X6GuP8AXMtn49021d3kUXWwbmzgk4zRGKumZVn+6l6P8AI+lI4lDYAHzcUhkUAYIzVUyNjg9xUZU7iST853fSu4+J2LTT5HH41r+GtRC2fiDTlia6lubZWS3jGXZgcZ9hg8k1zwGOvQ+la/w4dtN8XW8jy7kuCYn4xwwwP1xQzvy9xjWTbPJrLRNYi1WXSraW2FxNOFiiYFipY4xx1r6imjTRfC8NjG2TbxLGWx94gcn8TzXKeHfCKQfEy61EIWS1iLxFu8j8KfwBJro/F93FaWzwP8zFcsx7muGda/un2uEglrbU8U8bXSy+YQQG5Hv9a8kmilubzZGpkcAngcmu98WyLPLO0LEbMsV9a4jT72S2nlljA8xhtDMeAO9cjd9T1IpOWhz0kc32oxxxSeY7bQAp617D4Q0wC3gRx+5iH/fTdya53Tbm4upMp8w7tjAH0ru7G6htNNQYUKBz65q4rS5rVq3djSnkSNSYztUVxXi3VEVCsb5yOlHiPxJFGCEkH0rynxF4jaWR1jbcx4HtTs5bHHWxCgrIpa/es8jRxvyx+YisVFJp0YaVizkkmr0UGQOK3StoeJVq63Y3Spfst4GbPlv8r/T1rpTGQ1YiWpZsAHNdXDYSppUM7AkL8jH09KuN2eTjKkbqXVlFRipFXP40/wAv0qxDEKtI4ZTsNhgLf4VdjgGRxU0EWPQVeWHjGKpI5ZVHcqpBjipPJIBq7HCeOPzqcQHHTiqM+cx2jI7E0VqSW3PQ/hRRYpTR9PeNLGL7PmNFiccqyDBBrk9P1i6t2CXBM0fT0YfjXceMhugwPxrz9o/3nHSsZwUtz7aNRx2OoS4F3CTBL8xXAJ4I+teVapbtaalcJd3bGTcSEzgV3dkrK6spII7iuU+Jt1bW17Y2zKi3VyuTIcDb1wP0rlqYdrWJ2U8UmrS0OOkW9e6CW8kSmRgq/j6k1jahL++kjXeHV2G8kfMMnGMd8elVPt8lt4ght2tIJLZ3ILrcbpmVThyoAwCM5wcZr0f+ybOzmBjiDOOjv8xH09KiOHk3qKWIitUdB8OdF/svwrAkkheS5uhcuDn5c4AHPfArY8Q2SnJx+VVNAusWrRk/cYMK6PU7fzlyRwRxW1aOisLCzcnK55ncwsJCBkAVn3MJYE12txpxLNtSsq8sGUEbea4pRO9M4HU4zsPNcFq4ij8U+Hp51/dC8SOT/dLDP9a9N1y32IxIx2FeUeOXaK1ilXhop1YGpo6VERXV6bPatd+HYVnbS7jgE4STp+dcJrum3eixvJqURhiX+M9DXswhu723iebWJYhJGrn7NCke7IB+9yfyqsfD9gr+bJbC6mxxLcuZm/8AHs4/Cu9NPY8ppo+RvEF9Dd6hNLGkgc4UFmwAB3x6+1M0q5tFheO5knhkw7CRQHVjt+VSvb5upz0PSvo7xN8NNH1ze7RG3nPR0HevJ/Evwk1bTd0lg63UQ7dDWmjFY4i/aJ53gR0kwcLIvCt7j0qhtMZ/eISoOCM4qzc6VfWkrR3NrJGw67hj9arSROnDKV+tNaALsicjZJtyejjp+NWVtJ7eVZoJ12oc+fE/3Pf1FUACTip4kaVDHGyjHJBOCxoGbfifX7nWobIT6nfXcMCGNY7ptzJjvnvmtn4S3nhrTteN54jurmCVBttmjQ7EY/xlgcgjtxiuIlQxnbJGVYD6VGMA880uXSwH1Lrdt4fuvDDzaO8OoXlxIIbaaKYF5J5Dxux2HJPHRTXNx/DAaZr2l31leCVLF0Z964Z8HJPvzk15L4csome4vLTXk0i7tFEkSzFleRsHIQjvjj15r1zw5qnj2yn0+38Q2MV7p94yK12uDJCG7sV9PcfjSjGSatqY12vZS9H+R3yxgHOMg80yUEgE5+U4xVyNcRhQPb6U1kXlcDkdDXcfDt6lQrjgiltLkW95BLu2lHBz75qjdXhUdcDofasi5unJIXJBpNmtNuMlLsfSun3sJmjuCmxbqEMGOMFgen61538R7oK8jZIPOV9a0vB1yNe8CCKQgz2hxjPOOh/pXlmqzXb6leadqF1NIACYi7c49PyrxsXzQvY+8wVZSUX3PNfF+vRwSzJHgzMNoXuK5zQbeXUJ1Z2IBNT6lpa2+oT+YdxDEHPWnWd/Fp8WSypjnk1FPWKPak409md7YiDTbcKXUADn3rmNd8UJH5kKShIzyW/wrlNX8Ty3eY7NWc/3j0rDWwu7x98u5ifWuqMG9zzMRjYx2Y/VNXlvJCIt2z1PU1Sht2Y/MOa6Cz0B8DfxWza6Ii4+XJreMOiPDr5lTjsznLWzcgYWti005jjdwK6S30oADatXoNPIxhQK0VM8itj3LYx9P0wCQFl/Gu70DT45oHtbhcwyrtP+NZ1pZjIz1FdPo6hCvt3raCSPJr1ZTd2zzrWtLl0nUprSflkPyt/eXsarwfewa9b8beHzrWireWqBr21XOB1dO4/rXk4X8xUSjZnTTq+0j5mlBHmtKCHJ5HFZ1lJyM9a2YSGAwKaZlO6HiEAZAFSBBgd6fGuR9KkCen41SMrlcx7qKs7dpx1NFDA+jPFjDlfWuMaIbzXW+IX8y4c574rmG6nisj7q5Yso+RXjn7RNnc3ms28FtG8sjwxpGkQyzMTwMe5r2mwUllrPsNNGofHmMzor2+n6Ql2mf+ejMUU/h81FrrUNTznQ/h7aeH1sZdUWWfWokVrh2kOwydfu9CRwM98Vs3/+uU+tdd45j8vVpiO5zXH3334zUvcL9C1p8xifrgHg16hpsaX+lWso/iQfn0/pXkCyBOc16j8MLwXukTwnlreXH4MMj+tZVI6G+HlyyLU2mEZIUemBXO6xYbAxxivRp4gAcCuZ1+AeUx9q5ZI9KErnjXiOHAbj6mvFPiLhLFx/eYfzr3rxVCdr4zXh/wARLbdpUzDqjBv1rCH8RFVf4bPorQ5JX0PTXwTutIiM/wC4Kw/ijrF3ofgpbqwm8i7N2iq64OBySPpxXS+Goz/wjuk7zkCziHHT7grzb9pW4+zeEdIt4vlaS7ZsD0Cf/XrenH3mefJ6HP6B8aJP7QisNe04Sl2VBc2pw2T6oeD+BFeu3ZKEqwG6vjawmeHULe8fJ8uVXHqSDnivqHwp4t0/W9NhZ5mWfaPNZ1wN2OfpWs24WISTJNa0iy1EMt7axvkdeh/OvOde+HcLlm06Taf7jivYmiikQkHAIyMHIrkvGM9xZ28VlpwD6nft5FqBzgkfM59lGTTjUUgcWfPt9oU0VzcRxRllgby5JIxlQ3936+tYs1rJEeRn6V9NadoFlp+kxWEfKxr8zMMmRj95j7k1z2u+B7G8BdEEbno6f4VopE27HgZlkKbGYlfQ0jbSflBHqDXd674DvrMPJGiyxKM7gecVxUts6LkKdp6EjrVJ3EMgAlmjSZyI88+w74r0D4e+J54/E+l6dZq8NjNcJGY/OZuCe+Tj9K87xggNkD1ro/h4f+K80PHzf6XH+PNUt0ZYhfupejPqhFwxYfxDdUVw2wBh1XvViLOAxHtTLtB5bd8jiuo+H6nLamAk0ijOOuPrUFvCH5Jqxqas+D3U7frU+nw4AJ9M5NQaX0Os+Glyun6q9uzYiul2Nnpk1j/EzTpLa6jvoxiSF9j4/T+tV47oW91G0Zxht3Fdz4ngTVtGSYYKXMe0n0bsfz/nXJiYX1PfyvEuUOR9D5w8Z6LPdagLu2uGS3mUHao74rmh4di3Bpt0h9XOa9LuoWFrcWrZ3wMSoPp3FYHyk9Bg81nhrcvL1Q8wr14VLc3us56PSokACoBj2rRtdPTA4xWgIge34VYtI8k9q60jyJ1ZS3ZFb2KjHHNaENmvBx+lWYYOc4q4luCM1Zyt6lRLcA9BxVlIhjpzVyODIHGak8jbzVJGbepTWIDtWlYDYwyKqsDngVdthjGT/wDXpoiS0Oy0OXBA7HivNPiZ4a/sbVPtdqmLG7JZcDhG7r/UV3ekylWAziul1TSIfEWgT6fPgeYuUY/wOOhqrcysRTqezlfofOMLlCD2ras5s7cGsm/s59Nv5rS7UxzwuUdT61NZT+W/PSsVo7HdJXVzpbc9xV1FyOlZVtLvHy1rQOuzJIJNWjmYxxg8DNFWgoPUUU7CPdNWVnJb86wXjw23FdLq+Ewo/Gsd4sgn8ayaPuiXTYssuB3qDTs2vxyAPS88PcH3jn5/9Cra0i32qPU96yPFTJpvjzwNqpi4luZ9Kkk3H5Vlj3KMe7oKYIo+NP8ASGmYD95G5VhjnHrXE3cEsgXahA9TxXd+Li0es30CcNNGFX3yRXLazHtRGHyyw/Iw/ve9S31BOxgiBdxWVixHPHArtPhBfCHW7qzcgLcx5T/eXnH5E1x1w3IcfjTNF1B9M1e1vYzjyZVc+4zyPyzWctUaQbvc+j5kytc/rMe6Ij29K6NHWWEOhyrDcD7HpWRqcR8t/auWS0O+hLWx474vjKK4HSvDvHceNKvwB1TgfiK988Zp97PfNeK+JIVk3RyFQhddxbgYDAnNcq0mjqqfAz3dLuDTNHs0mxlII1VT1JCgcV4h8c9Uj8UXGl2Wm7ZDZeY0zA5RWbGBnueDkCtDxH4huvEd1J9neSKwztMy5VpB6IP4V9+prFvbeFI444AFRBgAcV20oNas8qc+iPPbbQWjlDS/M3qa6DTkuLFxJbStG/qpxWkYlHvTWiXryK0ZmmdDovi2a0/4/BgAZMsRxx6leh/StHwnqaeINTuNdlKl2Bt7SNT86Qg8tt/2iO2eBXnGuozpDYQufMum2k/3UHLH+laEMRt1RYsoEAC44wO1ZuCe5ak0exyvDcA5Ibnr0I+tUb2zCRvKlysaoMuJDgL+NcHa+JbuyXddOLiJRgCT7w+h61qWOrw6pMsupyeSqnMNnJ9z2Zz0ZvY8Cs+SUdmVzplPUHvtacW6RSQ6Wcb5ZFKm4Hov+x796de6HY3kSxS2sZA4BVcEV0Ukzs7gsWUnIyciqU8rrMSgyK6vZM8J55TTs4M891j4fxPuawmZW/uNWX4S0G/0zx3oRuYGCC7T5h0616fJqCocTQAr3Knn8qpR6gLjxDoiabGXiN2huSzAFAD0xQk00dTxtGtSlyvo99D1WIfIR04pl0QRle46U3zgGznAxVfzDIGxxgnFdh8izPniXMnHUZqjJMViwvGK0pwVbJJIzkisq8Xa5A79PpUtFJkUEm6T5ic5r03wbKuo6Dd2DsPMT95Hzz+FeVxAiUetdf4O1H7DrFtN1QttceorOceZHZgqvs6y8zA8X2RtNWW6UYSb74Hr0NcFfwG2vJI/4Qdy/Q17r8RNJDfaVjXKn99F9O9ePa1B5lrFcD70R2P9O1ecv3dT10PdxtP2tLm6oy0J61ctMB+lUYfQ1dhPzg13rY+fkblsoK/WrioBxVOzbKitONMgH1rVHPIlgXK5I6U8pvyBkYqGNyZAo79TV6MDHc1aIehmsnJ4p8H3hntV24i+U1R2nOc/Wgk2dPfa2a7bQp+nPFeeWFwA2Aa6rRbna4GeppowkjD+NXhrzYE16zQbkAjuQB27P/Q14+pPr0r6sEUN/YyW1yokilUo6nuDXzX4u0SXw7r9zYS52Kd0TH+ND0NTUj1OnDVLrkfQj0+4wQDyRXQWhAIJ6/yrkI22sCCeK3rK5BRQTmoizScep0Kv3oqtbyh17UVdzG59H6naF595yVqgYQZlU+vSujMquNsg/GqzWaCUSR8+1QfdEltCsNsDgZxXL/FXT5rr4c391ZAm/wBMaPU7fHXfCwfj6gMPxrrtymIA/eHaszxFeRx6LPaqR5sylMex6/pSdwOI8TalbatqFhqNhKslvc20c6leQAw3CqOsKr2O+QAMxAXPWsrwI8NhFe+HriNkk0m4MMJkOWe3cF42HtksPwqxr5kgijSQZRTlT61L2F1MC7QqGH41mscBsjitKWXcvtise8ck7VwM8VjJmkUfRPw91D+0vB2mTk5cR+U/1Q7f6Vq6gnB965v4bxx6foyaajKWjHmZHcn7x/OunvpY44C0jBVHUk1g2mjrp3UkeT+N4APMIGVrxTWowbrDAEbsHNev/EPxPolssoe+i3DsmW/lXgOseL9Je7JSSUruz9zFcu89D0Jp8jOgGF4HAqleHJzgH61MkyyxLJG25HAZW9QaqXDDJGa9JHispFMZwT1qMsRweasxwyztiCN5D/srmp5dEvJLeQNJDbOVIUudxB9cCk1cynVhT+J2OasHF1qV3etnYv8Ao8J9gfmP4n+VaqEk4ByfStLT9H0/TrOKDdJc+WuMn5QT3OKtmdYFH2eKOIH+6vP50WOOpmVNfCrmJDZXFzMZXhZYoziPf8oz3bn9Kt/YUXiWZB7JzVmUvLCzKSZB8w9x3FU1YPhgODRynJPMqknaKsaaar5FvFFGN3lrtDN1IqtNqNxKrZbAPQCqpXPNJt4qjz3a9xVkYjqan0iJH8QaZK4+dZ1ww4PWogvp2q9oqj+1rIntMv8AOiK1E5Ox6T1Axzn1qWNQGUZ+8MH61GnJGRnnmpc/Ln+6cius4CpeJ8vJz71lXWGwRnpj6Vs3I4OCOnesplyJFI5HzA0NFJlErl81etWKOCpIPX8arsuMHpx+dPU7SPXripsM9UMv9seE7e7HM9r8rjvt/wA8V5PrFksGo3Fs4/czjjPv0r0D4baggvZtPmY+Tcrt9gT/APX/AJ1i+OtKaHzQQfNt24P+z2rgxFM+qwlX21JNnkLRtBO8cg+ZDtNW4ipHvVnxFb/vIrtR8so2t7MKpQNxitaM+aNzw8TS9nNxNvTmBAz+tbMbZHHNc3ZSFZMdq3rR8gAYzXRE457lxEH51atXyCjHDDp71WAyM9KkVgCMZz61oZblt1LLnHSqkiLFNkjg1ZE29drdKiuFLKM846UEmWcxXJMY4PPWuj0q5+4e9YUqgnAH5VY06UxsAeBmgzmem6Pd7gorn/i/4c/tnw/9uto917Y5fjq0f8Q/rS6TdkMvP1rsrWZZogDhgRgg9xWmj0M1Jwakj5QRsGrdrciN8dq2/iV4cPh3xHLHEpFpPmWA9sHqPwP9K5ZPWuVrldj0k1NXR1dncjZxRWXY3GExmiqRi4O59nCOMDpzRtXIpwXI4OaUoadz7djHQH8e9UdS0qO7RSSFdehxxmtEq3GVNMLY9aBHkHjrS5tC1ex8RzRkwxqbS9kXkGFyNsn/AAFsfgTWDqWoNNYiFznZISD7V6p4+kgn0qXTbnBhuYm3B+jDOCp+ua8Q0+EvJdWBMoaxkEWJTl2jI/duT3yOvuDWM79BpEc0ue5qOzQ3F/axEZ3yoNv496t3sIhyqAfWneF4vM8QWjsD5URLsxHGQO5rCeiNk0tz0+a+ezZp7AETjKqyrnnHcelR6RNe699nntrb7cGgxO0smFD7jg88Zx6elZ+pXkiWbnTrhILjPyuY96fln0rtfhvGsXhW3CBcM8jEjuSxzn3rOMZKOqLpYqnKfJBpvyPIPHPwv1O+eaeW7sLRWJIjQM2K8F8UeB5dNkmY30UvlgnAQjNfbPi6LNk788cV82a+ijxEplAdN/RuRntXOlyz00uehWqy9g5PWyKmm6WLfTbaOefJiiVW2D296trHax4KWysf70h3fp0p03zg44yaSJsDDjIHFeoopHwNXG1qu8hkty5GwHavoOBVY5Kck8VYkjDEFeneomXbQzmvcrMOetR4xkHoalYdc0wrng1JSY1CysAD83UVVuIvLmLqMRv29DU74xhjg9j6Uinz0ZdpY98Dr7ikMjCnuKNn4VZhtpJLVXOAASM9T+VN8lFYAl2J9TgUCuRJgNjrzV3SI3/ta0O0hfNXk8d6auEbCqFPqBVvTcjUrUnn96P501uJ7HeRnvjHNTx4zz0PBqo0oAHrirNl+8cK3p17V1HG9COZMxDPXpWXIP3oP4cVt3iYDbTnvzWVKv7w9qBorFMbgeSKruB2PzVejt57iTEEUkjHsqk1ftvC+oSvmXyrdT/z0bLfkOals0jTlP4UZ+mTta3UM6E5RgeD2r07xXEmpabaamoBWZPLlwO/euZs/DGlw4Oo6wqD+6igfzruNDTRZdMfSbG+luVfnDEMw9xzWNXU9nLVOleMjwrUbHd9rsJBg8mMn17VyEWVZgRgg4Ir3Xxb4Inlxe6PMlwYfvKTgnH8vxrx7xTYPZ6n5hRkWX7ykYKuOorkpXpzs9ma5jSUoqouhAhGQQelbNnPwMHBrnoWyME/hV+0l2sMV2pnhyVzpY33d/zqdCMc1m275A5q8jAY75rVMyZZQ54bgjp704jK59KgD7uc/NTt2OlO5DQsigjKjnFU9zJICe9XFPJzUdwgYHAz3FBEkamm3IDg55rtNHuwAAeteZ2kzJIFyMV1OlXI3AbqadjKRr/EnQV8R+GZVhUNeW376E9yR1X8RXziMqSCMEHpX1Np10GUYNeJfFzw6NH137ZapizvcuuBwr/xD+tKpG6ubYadnyM4uJ9pOM59KKgVs5orC51tH3avyHnpTmkGQVGeaqz6jZxjM08UXUHccYrB1PxnpNmjGN3ndeiqMDrjqar1PrKlenT+KVjrRICDRuQdcAe9eW6l8QJxkWkMcWeMn5jXL6n4n1K+4kuZGBHAzgZ+gqbI4amaUo/Crnq2v3OhmXfqL2rsg2qPvMPpivLfHWp6Pp2qWes6ZZPcLbxvFeQ4wJYDzkd8ofm+mayo5y9tuY5def8AgOf6VBLICQcAkc4IyD7Gnc43mlRy0VkV4dat7+5keK3ijQnIH3hj2zU8t0ZJYyz4jX+EcDH0rkLSIwajeWTHy5YiZYMcB4ieAP8AdJx9MVorPIse2bhj+tSjlrzm5e9Jsu6zrrPiKLKovQCvc/hhcifwHpUvHEZQ8fxBiDXzl5ZllHHevo7wDELbwJpUQxnyt/HuSf61lW2PVyRfvZJdv1F8ZT+Xpb4I+btXzX4oyL5pAOVbNe5+N7xirRqSe30rxbxLCwVmIwTXn1Hrc+xUfd5SCM71GOQeaeflU4/GqGlSS/ZwUjL4+U56VZkjldvmkSMdSBya9WL5kmfnFam6VSUH0YM4Wq8twgzkg0828QOWd5D7nH8qA6R/cRE+gobMyuTI4+WNsdi3y0LATjzJQueyDP61KZN/rSKvpxUD2ES3hBztLEnq5zU6pvkKH7jDA9qFX5hnipVGCcimkSyqoktJCGXch+8Mdfem3MBG2VDmInIOensa1gonj2v94VT8trZjhd0Z+8lOwcxTQhnz1NWLM4u4sjB8wEVFNCIW8yH5oW6f7PtUloT9qt8AtlxgD60luN7HVRlnjVST65PetfT8gqqcsx6CksdGcIsl832eIDO0/fI9cdh7mlm8RW1oDFo0Ad+nmZ4/Fup/CuhyXQxVF2vN2RqNpssm03LiBRzg8t+X+NVLm80XT25/0iUcc/N+g4/WsOZ77UMtdTMVb/lmvyp+Xf8AGq09sqKOMHNKzZSqQh8C+82J/Fc7r5dnEkMfvz+gwKybjVLy44mnkKnPyg7R+QqsFCufyp6xDcx6d6VrClVnLdjUc8rt4Nb3h+6e0v4ZlYhQQCKxo4i3K9RzV2AFCMEg9etDV1YVOo6c1JdD07X4biwuIdR0eZk89d4zyGPdSK5vxtpEHi3ww2p6dEI7uMHfEOqOvVf6j8q6zwzJ/bPhdrZ3DXMQ3ofcdRWL4aE9t4slsokJg1CJmI7I6DIb+Y/GuWStofVRtWh6nz3EGDYbg96uxtgDHWtn4kaZFpfim8S2GIncttwRsbuv0rAgbNXTnzK6PAxFGVGbhLdGvazkgDNacUpcAd8d652Nyjg9q1bacYGSMd62TOOaNRCA3WpDIQT3qsrqV470FwF+8KtGbLKtzx696eZMjgZNUfN+br704SZ6fWnchoY5KTDHQnpWxYXGGXPUViynJB4zUlvIQRk8dadzOSPQdKu8kc8d/arXirSYvEnh64sW4lxvhb+646f4Vy+nXAG0hsV1em3Wdvzc1cTPVO6PmmeKS2uJIZlKSIxVlPUEdRRXpPxh8OmHU4tVsoiYrv5ZVUdJB3/EfyornlBp2PThUUopnR3N7NPInmSO2WJyT2YYNUWleSKNm6k+U/sQeDT74fKyoMYO9Pp3FRABriaJeksYkX/eFSJ6j3bexOeM4xQemelRxtlc9SeTTi3YcE0AySN/Lk6dfmx7HqKgmzHuHUKcH6dqfg/Lgc5/KpltpZSW2E4GG9xTAw/EGnvdPbT2kiR3lu+UkfhSp6q3sRTrF4r+1imhO6JwcEjp2I+oIrXdba3kzcTAnsifMaw0dtI1OR7SJY9Pv5AAJBnyZjwCPZun1x60tjoh+8hy9Vt6dv1+8uppzRnIHyep4Ar27wTdRnwZaSK6lYUaMkdyCe9eOpbTSPm8kd1HY8D8q9ODReG/AFsjJ88iGUr7sc4/lWNfSJ7GQKUq7ttY5/xBfpNcOARk9q4zXbJpbJ5cEgjIPtWVFd3+sXl/9llgWTb5zLJJtIQdQo7nHau1KC90SG4Q74REPlKGMYrzm01c+z5WeQWN2bW4lhfo3IHvV5pWPzZ4PWs3xc0Meo77T5Qw6dwQazItRfo+TXbh5+5ZnxedUFHEuS6nTLIM4PemsVyTWJFebuO1XIZHkHGcVte55FrF4PwSOtSRtk1VUcVNCcHJ6UEsvbeBnrT+o/rSwEEYqXycglDwapGdxiNg7c1Z4dcHgis+QlCc1LFLkDPamhNDXX7OxIGYz95aLctp1/a3cALxrIGQZwc+masOA6cioLdmjnWM8xsw464NFgUmtTXlnvdUO+8l/d5/1ScLn37k+5q1ZW4BCjAxgUkCcEDj6VcgjO7JHHFbRikc05ObvIvQxoqj196zbwnzCFGABnmtMuAqjoOR9KozqGZj0JGOf0qhIxmzuznB7U4k+cpHAx1psylWBYEkU2FtykAc5yKks1LUbewxT+VfGKbpwLrgY49qnugFIJ6nj8aQHUeB9SNjfqFOFY5rr7/TbmLxNZ6hpcRZd4kz0XYeHBP0Nee+D9OuNW1mG3tztIO+R+oRB1NezS4t4khizsQYGTzXJiKih6n1GSU51Ya7I4Tx54O03XtRkuZpZo9wGVjAHI75NcJf+AtMgU/Z5rsEdywP9K9L8Qapb2SnzHUH3rkP7WhvnKxyKc9ga81VZR+Fn0U8HRqu9SKbPNtV8PT2pJt5PNA7EYaseKRo32yAq4PfqK9Y1LSpngLhciuB1nT97nI2SD7rf4100cW07VPvPGx+RwcXPD79itFPleGqVZht571ipMY2KPkMpwQasJOGHWvTTufJSg4uzNASDPB5qdXwM1mCcHpgYp32rsOR60GbReZsgc0+NwSc1R835euaI5ju4p3M2joLK4KMBniul066II54rhxLsCnvWzZXeVUE81adjNo76GSO4i2TKrqOQGFFYVjdYXk9vWitTOxyI1kPbqUADRNtJNSm9A1a3CgBT9zHoR0rObS2jmnuLk+XbE7ynf8AKrejR+dPC8sZcxZC8YGM8Z/CuM9J2NWK1d5CEUk7qttDFAC11Kq99vVvyqeQSvwXEaHsnGfxpi2ka9RknmgRXF0OBa25J7PL0/Kh47m5GJpWK/3V4H5VeCoucYwKUSL0FMCtb6bHEBkCrcOnaffypY6nkWlwfKdkwCuehB7YODmmvIWAA61VmyYmVcbmGOaRpTm4zUuxHoLz3WunRLvH25Lj7O2epweT+I5rpfjFqjWdq1soGxFCrg9vStHwb4dgvfElp4m2x+d9mdJDjJMy4XPt8przj406ujXc4LMjeYqrHnO4n0rhxNRfCj7zKsNCHNUgviscp4Jia+1W5uQCkifuIyOC+7rk+gFd/rt6NF0B4nnVii4BxtH/ANeuU0i+Xw/pn9o6lIquVyFbsD/WvNfFviu98TXrRRErZg8Bf4//AK1YQp82iPSxmLhh43e/QydU1CfUb/zt5Cqf3YHb3rVt8ywpLjG7r6ZqLTNIeQguNor0LQvD8N7YPZNiNm5STH3W7H6etdsIaaHwGNxinK71OUsIN7AmuitbYDHFZX2ebTb+W1vIzHLE21lPY/4V0tgFKKVwQa0icU290Mex3JwKqeV5bYPFdEifLz0qtfWYdSy9apozUjPt2OfpV+FwR6VmD92+G4Iq0ku4qV4J5oQ2ixdQhlyOprMAKPzwK34VDoOefeqt/Z8EqBnrTaJjLoUmuMRHHLVasYgwjfqSwNZzQkAkc+3pVrTpys0admcD6UJ6jlsdHAnc8Y4q6jFF6c461TgOMBj3yasTEoAd1dByPRgsxdmUdTT5EzDkj7vP9aq2mN474Oc+1a23eNuRgDNAXOevV64+uKoQgCU7eh4zWjqY25QcY/X0rOg5mGcZJqWaI2dNYqxB+nSrOoH5eOvT8aZbJsZW6AjNLqjjHydhTewR1Z6v8I9MFt4clv2XE125wx/uLwP1zW7rE3kWkspOCBU/g2HyPB+lp6WyE/UjP9axvG0pj0mYjrivJxO9z9By6mqdOMF2PAvGGsXOq6zJBHIwRTzg9qg0g2EVxsFwPOXrg8isHWL+OymnlmYqJJRHkDPWuC0PUZNP+IVzbzyHyp52Q5PQn7v9BXnwg53fY9Wc1Cy7n1p4Vv0mgW2uiHVhhJPX2rM8b+G9qmeFeOpxXmvw68TTR6/f6RqMjsUkypY/wnoV9MV9AafjU9Pkt5wDNGME+o7GtErqzJemp82a9aMNzqv7xOvuKxY5twHJNen+OdHNjeMyr8pJry6/i+yXbBR8jfMvtXfg6zfuPofK55gVF/WIddy7GzFQc1NGAGrOjm4FWFm6816B8y0Xi/vQjkNntVLzhu65/Gl84DGKdyGjXD7l6g1ds5tpHPSsBLogcDJ6Vf0/ez9Mf0qkZSR19rcfJ1GD60VStlIXLN+tFUZFizuYY2+YBg3DFuSasxkJP8nEbU7xN4Q1HRnkMEbzRLyVYfOo9cdx7isFLt3gAZz+Fcqlc9arRlTlaSsdV9ojUYLBselRPc7flHJNYVrdDgH6VpRyK4B9OlUYWsWd7OOTinq2BzVbzgenNPQ8jvTEW4sFSDVK8co3HQ1YV8dKZdRZQsfypAnqbXgLVnN3Lps1xJAkuGhdWxiToPzyRXlPxMgvLfWpL2aKW5u45PLKseF54b29D712EREI3sdrg8EVseKLZfEOhLq8aBrqAeVeIByw7N+IGfqD61w4qjdqfY+lyrMZxg6MHZ20Pny+h1LWplfU5T5a/diX7o/xrc0nRIYwMKB+FaFzbiGdkIGOoPqPWtDS1DDA61tTta6PLxdetUk/avUfbWUa4wtbWmnyZlxSW8a8hgPapWhMbbscGuhHmy1NbxT4eHiTSfttioOqWqZ2jrMg/h+o7flXnelXmxwjk46c9q9T8L6l5E6kHoawvir4XWzkGv6ZGBZ3Df6Si9I5D/F9D/P60muqClL/AJdyK1k6yx4z1qxs/hY8VzOi6gVxG557E9xXUI6vGGHXFCdxyXKzJ1G0BUso5H61lQExyc9jjmuomXKkd8Vi3tvzuXg0NFKRPBcdM/pV6OQOAM/nXPRyleD+BrQt7gHGTzQmJxJ7qFQS4GG7j1qssC/aoJIjjLjIrSyJU55qk8LJdwGI4UuAwP1p9Sbs143wwOR0wCamkO63Vic5FV1wxXrjGKnumG0ADnHpW5g2Q2j/AL0qMgk4wK34wRB83HHXH5CubsjsuFbOQO1dLFzFuPUdKETIw9VjAcMeM84FUYoQ0q4A9/Y1p6pll+UDcD+QqKxgCqQxOc9qVrstMuhc264/h9azbuXzMjvyK0JpgqEL0+7z71hSZSYqzHOetEi6e59L+En8/wAKaUy9DbJ+gxWJ43jL6XN9Kn+FN6LvwZZqOsBaE/gcj9CKseKIfMtJkx615WJifoOBnzQi12R8c/EJZIrG7kjQMYZVcg+nIzXmXiSYtrr3URIMgSVT+A5r3XxfZBdQuoJFBWUFcEcH2ryfX9BBsUNpud4c7Q3XbnO38K5MLVjCVpHfiIucdDrfDl6upa/peqQZ3TQeXPgdHUjOa+l/C2o7VtbnOQMRSf7p6H8DXxj4V1K70UG7hV3sGYLMB/yzb+lfRPwz8V2moQfZzMpSZNqtnoe2aqpTdOXl0Jp1VUXmelfEbSluLRpEXORuFfPPiW3Ko5x80Zz+Hevp+WRNT8NxyEgnbg898V8++MrYRX80ZHDZFJS5JqaMsRSVajKmzgI5QT1qdJSTUCWzrkMcYP41cSJUHPWvbR+fVLJ2HJvYnA46VYWHHLEZ9KYJwo4xmoZJyT1xTMdS/GY4+at2V5+9wOlYnmEjk9asW7EMMfjTTIlHudYtwSv3gKKyreUlcZxj0oqrmFkfYEsVjrVquSsqHkMp5H415N468EWELySpK0M+eJgOHPoy/wBRU2j63cadPvgk2g9U7H8KteIfEttfTQC+s2mtWys6bsEAjsf88Vzyp3+E+m/tCjXhy1lZnh/2nbJgHpxWraXDOAM8VmeNNLm0adJtPU3MU7ExW8I3EKOp+gHrVGw1IucqeQdrD0Poa3rYaph2uc8yUGlc7OIqvGetWEbpgVjWl1vAOelaUUwwKyMWX4Rz8xwOtSyTDaAORVPzSRjNSQnPXtQTYqXi5B9av+GNT/s68zMC9tIDHNH/AHkPX8R1FQ3abo8gcis45X5hxSaTVmaU6jpyU47oj8d+Hvsl1m2O+GQebbOOjqedv9R+NcnYzbJFbP1r1TQ5I9d0xtEumCzDMlnL/cbqU+h6j/69ee+I9IudMnaea3kijL7XypAD+o9jXEv3UuV7M9jEQWJpqvD5mpA6uFYHgdK0kZXjw3HtXL6ZeBQFOa24ZuATXanc8aSJUZ7e6EiHHYgd67zQL+31Cxksb1RLBMhjdW6EGuELB8gjg1Np149jcqAx29qq9jCcb6nJeMfD9x4X15rVmZ7Z/wB5bS/309D7joavaHqKyRhGOCBXpGuWFv4x8OtZyMFu4/ntpT/A/p9D0NeJIbjTdQlt7pGjnicpIjdQRUNcrubQl7WNnud8G3r7VVnw2cCobK7EsY57VI7DkiqJs0ZV1FhiariTacVqTKWGeDWdcQ4w24Ad6lrUtMv2N0VIycitUos3lyRcEMMj1rmkljT7gLNV+zvHMkat8qswGBVRFKPU3VGBk9+fpUV5IQmB1HSnoXYnaAOaYbctKAzcDqR3rc5epY0m33uWbjnIrcMiqhC5OPSsczJCFSPAIO0mtC2O+LGecc4oEzLvJS03XHapIMqoJzyOfrUM65uM4xzj8atRcDB5LDNBQkke7Bb+EYNZl2A0nnDkE4P1rRu5RHHyeowfpWTLOghdAPm6g+lQzSOh6p8FNU2T3+muQC4E8Y9SOG/TFekaxDuiz6ivmjw14gk0TXLS/TJEEmWUfxJ0YflmvptJ4r3T45oHDwyqJI2HdSMiuPEw/E+uyXEc9Pk6x/I+ePiXpjQ3hmVehzXmF1bAXBIH7uT5l9vUV9H+PdJF3A+FzivC9SsjBO0EnHOUJ7H0rxaisz6eL5lY5NdIntLt7zSTGsrrtmglXdFOvow/rTEsbKK5NzpV3L4e1DO42t0cwu3oj9CPrzXU2qYbaRgjrXbeGLCzvgba9toZ4X4ZJEDA/ga6cPimvcnqjmrYZP3ouzOY0L4keJvD9m1rqOlre2zn/W20g5I5yK5/xF47ttTuPMaxvoWPJDRg/wBa9WHwg0LUbS+uLK4vtMkSVhGLab93jjjacivG/GPhTUNHv2gg1Vp0DfelQZ/Sup+wktdDB/WI3WjK8N6l0JZYY5hGmCS6EAZJx+eD+VAlL5q/4X8R3Xh+z1Wyu0iumu4AkcgGPLcKyhyCOfldhj3rIiYbQAeK74PRWZ8djaUI1Hy/P1Latke9J6c00MRmjdn0qjhsSpwfSp4jggDvUCjvg1OgJb6UIzkaEGWHJx9aKZGxA9aKqxjY9XMpDDH4Uk7CRCG64qDfnFJuzg1mbNFewtV+3rIHdJ0VlidWIK7uorD1/SVdFMSJBfRjb5iqAs2P7wHc+tdCf3cu5etWNUtxeWvmJ94jr711wxM0uWWq7MSk47HBQWeoW5K3MBjIxkg7l554YcGteyZzhWHNbOi6kLfdDcRrPay8SwP6+oPZh61du9MgVfOsGM0PXBHzp7MP61yytzXWiOhrmV0UIovl3McDrUTXkccgReeKfqEnkWZeQ7RjHpWTaQl4/tV23kWwP326v7KO5pN2M4py2Ogst1zCyqhLdc56fWqc8ljbNtlY3Un9yM4QfVu/4VXa6e6VYYlMFnniMHlvdj3ovIFRAI1xgc0tWPmjDRalmLWruP5bTZaR9AIVwfz611/2u61bRDfQSG5lt12X1lMN8c0f98Kf1xXnsMm1wD9PpXS+Gb+fT9Tga2+Z3YJs7PnjBrOcOZHdg8XKnO0tUzl/Ffhw6bLZ32kxStpmoAtCoBYxOPvJ9B29qoW1w8bCO5R0b0YYr3XxhPaeEdBZbeEqrSFggOfnbrj2ri7KytPF9lIrMkd51UZBBP1rzljXCVrXPoKuQRqx54SsziHuQOhzihrjcoJrP8QWV3ol89tdxkYOATVNLl+7YHpXo06qqLmjsfL4jCzoTdOorNHc6DqhgkUbv1qL4k6INZtBrenIGvYExcIo5lQfxe5H6iuWtbvb1OO9dp4e1RkCsT8vvWq95WON3pvmR5to12VKrk7T0Oa31uo0HL59AOapfEXQG0zUf7SseNMvHLBV4EUh5K+wPUVj6ZdgfK2CRULR2Zu0pLmR06yvL8qLtHqaz7mJtx3E8VLBc85yKlnIkBYde9WSnYzv9Ww44q3bMDPET/fHP41XnQMnHWi2OZIxkj5h0oW43qjsIZlRxtPU8jvinTyAfcGM9cDjFZNoWQ7pCBgYqWe6jZsbiSevpW5zNajkMksnJ4LVu2UgjtyM84Arn4pfmfjBPp2q1bTv5q8ZHp6igTV0TXcipJISSWznGalWUJCH6FT+GKhFhNcS+YOF4GTWjBpof5ZX3n0HQUDOfv5pJXKRhjznIHQVFDp1xK2SNgbj5q66eGC3gURqinpnvWdLMEib1PNTYq99jNi0mKCQ+axJ6n3r1f4Ya+ghGiXL4KZNsT3HUp/UV5ZPdZxIzA54FVXv5BKstu7JJGwZWU4II6GpnBTjZnVgsVLC1VUXzPonV7Xzozxn2rx/xr4e3szovvxXongfxZF4ksPKuCqapEv72Mfxj++vt6jtUut2CyBvlzXiVqTi7M/QcNiIVoKcHoz54aN45dsvEi8ZP8X1rqvCFwE1CPJx61p+JPDocs8ajP0rkYzPp9x82QV6HvXJbkZ2J8x7locmPDjyk/6xmf8AM14V48lE2qSH3Nex6fdqngqB8jHl14V4jn82/kb3Jrob2MZaXOE1Bv8ATpO2DilgPQg5qOcGS6kbrljU0K847V7NNWSR8LiZKU5PzZaXke4qaKPJPHGabEB6Y7VZjHzfrWh58mKi4PNTom1u1Jt2k55p4BX6mmYyY4Diim4LKOCcdqKehnY9OBIGcj60Fsnjt0qJZMAg9acw2qHJxiszdj3OR71raGFuRLAeDjpWMjcEnjjg+9S2Nw1vcxy5wen1poHsY2sxvZatwMIx5+taVpdM+143KEDG4Grvii1W6i89BncM5965ezuGCsinrSY73V0bGpapJPiCEIzA8uUBrPuFMkq+exd8cE9vpT7UqhLDGfemXAxLuBzntSshucno2T2ow3TpTlbzpmDdqigbDZ5FNY4vVVOSxzTM3oR3EW24IA6da1NMuRaahZTv/wAsZVZvcAg1BfIBPHnr/Om3UZZQw4xwB60nsa0pWaZ6r8arF77wu81qfmTEqMBn8a+Yfht4ml0Txelpfu8P7x9pc4Doxzj6hun1NfUfgfV4PE3hRtLupFe8tE8tlPVk/hb+n4V4H8SvA32TVGLRfKGLRyY/SvDqxVOo1PZn6Lha3t6MZ0z1f4jaTD4i8JjUoAGniX5mX+IdjXgMbzBmR/l2nBJru/AHi660m1m0PWWaW1uoylvM3PzAZ2H/AGh+o5FcNrY8nWJV5EZOQK6cI3Cbg+up5GeUo1KUa0d07FqKVUcYGT6mug0m8IARm71ykLE4wK17BihyRXopnyFRaHo1kYNT06XT79Q9vMu1h6ehHuK8k13S7nw9q0ljc5O35opO0iHowr0TRZvu8/jWl4s0IeJ9AKRKP7RtgXt27t6ofY/zq2rq5lTnySs9meXWd1kcnJrWin3J1rk4ZWjJVwVZThgRg5rUtLgBetQpHTOFjYJByaiiOJkI/vg4qv5uehqxpiCbUbaMnh5AP1q0zN6GiFckgZJJzmr1np8zqBswM5zW7bWESHcVGBnk88VcDxoMcdOK3OdszrbSQHUsQx/PNaltbQ2+3dtBBP1qs9+sf3TnHSqN1qGXYBuMdKAtc2J7qJUwG57/AEqv9s2xjYw3H865ya7LHqSckCpLa4Jc5JwRgmgOU0rq6ZpCB908isu5mJbknJq1MAsQcnkHB+hrLuFIBK5xQykQPc4WQZwRyKbbOwXB5J61XkGJkZe1TwLtl28tg/hUFGjZTz2l3Dc2kjwzxHKOh5Fev+FfGNvr0aWt/st9TAxtzhZvdff2rx8YAwfXt3qKZjglSQQcgg4INRVpRqLU7cDmFTCTvHVdj3fUbEMGBWuG8Q6KkgYhQG+lN8HfEEqi2XiFiyL8q3Y5I9n9frXVa3LbTWwltpEkjYZDIcg/jXk1cO4OzPtsHjqeJjzU38jh21KSw8Of2e5Lbc4PpXl+sSYeViexNdr4puRGGCkc151qTvI+3BAz82aVKjKckuhOOxkKFNtvV7GSkRGR3PU1PDCQOKtR25IGRwKspBtB6c17Nj4WdW5WRCCMjrzV2JRgEDkU1lGARzg09c5AHegwk7j8A4A6fzqSKLIGQcDilhUdG4q3sORjHPWqSM2yuUKMcYJ9aKlZefmBwaKqwro7EuGTC43Cn+YWjCgdqplyHIHTG4fSno/I5rA6CzH1AJziny9j2HNQBsEn0qRHyrehHAoA19NmFxGYWOR2rltQtWtb5kQdSSBV21uTa3IJPy5rR8QW4uoI7qHG7rxTeoLQwUbAIcEDOCamliYQh1O5R3pqTRuihxhmIU/WrUkLWpZGbdGw70hNalCCXdyevvU7ERHzQd74wPaqd3KrARxKWOcYFWrTT7mcDefKhHrQDWhallWS3jY/6xeoHWny2s88SkHy4x1J6n6CniS109T5YEko7moo7x7wFDxjkCgFoO068OgXi3mnSFbpDgMec56gj0Nei22s6P4zshBdKlvqBGGgkPDH1Q9/515Lcqxm2seTU5KZ+zt98DOfQ1hWw8aysz08DmVTBv3dV1R1N94Gs7O+Av8AedNZsuBwyYOcg1wXxUXR5vEf/FOJILVI1X5s53d+tbVxresNZizlvpJbcDAEmGYD0z1rA+wBXLEZJOSTyaxoYaVLR69juzHNaWJglBNPqYun256SAitOKDaecgdqupbKOoGaUxMDtH4V2JWPAk7ljTpTEw9K7LSLna6FT71wcTEPtbj1rb0y6YYBPSqRhNXKHxY8LklvEWmR5RsfbI0H3T/z0+h7/nXm1vcbWxng19FaTcpJH5coVo3G1lYZBB6j6V4v8SvCjeGtV8+0UnSrpiYSP+WbdSh/p7VE4295HRh6nN+7l8jPjnBIAPPYVe0ecrq9mWP/AC2Xj8a5eK4PA/KtbTpg15bsx+YSA/rSg7mk4WPTJNRznaTjIx79qqteSZxnn+dUIpMkE9+KC3O4HBzXUcli5vLrnOCCc571VuJCCcbiV4PFN80Z3g4B7+tLHL94L8p9M0DRB5mcAdGPXvV2yBMgCkkZySe9Uyf9JHBK/TNTxylH2g4YnHHQUCZvvEHjK+o9Kxrw4j4B9efStK0kd1ViS2OnNU7iP97ImABkkUCWhjn7xFaMcP7kTEYwMMPWqUyhHO3g9B7VJBcTiCRNxYZzzzUlPyJLh2UgrTj8yKcZNR3RwFyw5pUJEGQe/Wh7iIhH1z27VPb3E8GBFNJGCMFVbg1XkkfGRUDXLAcAZp27jjKUXeLsWroNNlpHLH3rIubUbs4461M15MXABGPpSh2lzu5H0oSWyCU5SfNJ3KQjFI2BgjnFXmRSegzmoJYwM44GKLCvchiUM5OKnEWcN0xxmo4UABq2oJUbvShITIo02kEirORsOeDnFRsMk46HtSM2AR2FMljJnG4gEUVVnbDcnrRSCx13/L2n+5SRdfxoorI6Sf8A5Z/hUsP/ACzoopCK990rY08k6Ic880UUwOWvvlu4gOAZO1bOqEnTySTkdD+FFFIpkfh9FJBKgnHXFXdUZghAYgexoopkMxZv+PUnv61a0b/WfhRRSGJcDN/z/eqhqBI1EYPUUUUDJpeq/wCe1PH3DRRQBFL696B90UUUCM8k/wBppWlaE/aSM8c0UUGcjq9FJ8vrUPxRVX+Hepl1DFdjLkZwdw5FFFU9iaf8SPqj58XtWtppP2q2/wB8UUVhT3PUq7Hbg/K34U1OS2fUfyoortPNEB+U/Sli5fnn5qKKQE83ES4/vUtv/q8989aKKAext6aB5RGOMCi7A39KKKCUYFz95vrUtp/rm/3aKKnqV0KV0cvz2q7B/qaKKOoug1/uCqT9TRRVCRUbgnHpU0J7ds0UUDexMf46if8A1Sf57UUUyUQKelWkPB+lFFJDYSfwfWoU6iiigkpXX3vxoooqS47H/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The laryngeal mask airway (LMA) allows flexible bronchoscopy and ventilation to be performed under general anesthesia. The device can also serve as an excellent rescue airway.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Marquette, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_36_5697=[""].join("\n");
var outline_f5_36_5697=null;
var title_f5_36_5698="3D SHAX view of nonclassic MVP";
var content_f5_36_5698=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1166px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/83603/3D_SHAX_nonclass_MVP_video.mp4?title=3D+SHAX+view+of+nonclassic+MVP\" style=\"width:512px;height:400px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Three-dimensional short-axis echocardiographic view of nonclassic mitral valve prolapse with flail posterior leaflet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Images from a patient with fibroelastic deficiency with flail P2 scallop. Note focal involvement of the middle posterior scallop.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_36_5698=[""].join("\n");
var outline_f5_36_5698=null;
var title_f5_36_5699="Histoplasmosis lung granuloma";
var content_f5_36_5699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary histoplasmosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph of an hematoxylin and eosin-stained section of lung (low power) from a patient with histoplasmosis. Note the granuloma and inflammation in the surrounding lung tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_36_5699=[""].join("\n");
var outline_f5_36_5699=null;
var title_f5_36_5700="Hypnic headache";
var content_f5_36_5700=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypnic headache",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/36/5700/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/36/5700/contributors\">",
"     F Michael Cutrer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/36/5700/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/36/5700/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/36/5700/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/36/5700/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/36/5700/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypnic headache is one of several relatively uncommon headache syndromes that may occur either as a primary headache or as a headache secondary to potentially malignant processes. Careful evaluation for underlying causes is important for these uncommon types of headache.",
"   </p>",
"   <p>",
"    This topic will review hypnic headache. Other types of uncommon primary headache disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13714?source=see_link\">",
"     \"Primary stabbing headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22101?source=see_link\">",
"     \"Primary cough headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44356?source=see_link\">",
"     \"Primary exertional headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16054?source=see_link\">",
"     \"Primary headache associated with sexual activity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12601?source=see_link\">",
"     \"Thunderclap headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16243?source=see_link\">",
"     \"Nummular headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Also known as \"alarm clock\" headache, hypnic headache is characterized by episodes of dull head pain that develop only during sleep and awaken the sufferer from sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/1\">",
"     1",
"    </a>",
"    ]. It is one of the few headache disorders to occur almost exclusively in later life.",
"   </p>",
"   <p>",
"    Hypnic headaches typically occur frequently (&ge;15 days per month), and persist for at least 15 minutes after awakening the patient. They generally last no more than three hours, although longer durations may occur. About two-thirds of hypnic headaches occur bilaterally. The headaches are usually of mild to moderate intensity but may be severe in about 20 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While current diagnostic criteria for hypnic headache require dull head pain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/2\">",
"     2",
"    </a>",
"    ], throbbing pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    migraine features are not uncommon in patients with hypnic headache. A study that reviewed 71 cases of hypnic headache found that pulsatile headache was present in 38 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/3\">",
"     3",
"    </a>",
"    ]. In two of the largest series of patients with hypnic headaches, involving 22 subjects from France and 17 from Taiwan, approximately one-quarter of subjects reported a headache that was not dull [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In most of these patients, the headache was throbbing or pulsatile.",
"   </p>",
"   <p>",
"    The onset of hypnic headache is usually after age 50 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/2\">",
"     2",
"    </a>",
"    ]. In the series of 22 adults from France, onset before age 50 was reported in approximately one-quarter of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/5\">",
"     5",
"    </a>",
"    ]. The youngest age at onset was 41 years.",
"   </p>",
"   <p>",
"    According to current diagnostic criteria, hypnic headaches are not accompanied by the autonomic symptoms (tearing, runny nose, ptosis, or miosis) that can be prominent in cluster headache or the paroxysmal hemicranias [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/2\">",
"     2",
"    </a>",
"    ]. Hypnic headaches may be accompanied by no more than one of the following: nausea, photophobia, or phonophobia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of hypnic headache includes both primary and secondary headaches, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cluster headache",
"     </li>",
"     <li>",
"      Chronic and episodic paroxysmal hemicrania",
"     </li>",
"     <li>",
"      Nocturnal seizures with postictal headache",
"     </li>",
"     <li>",
"      Obstructive sleep apnea with headache",
"     </li>",
"     <li>",
"      Drug withdrawal headache [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pheochromocytoma",
"     </li>",
"     <li>",
"      Temporal arteritis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Migraine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differential also includes headache resulting from structural causes, such as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary or metastatic tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Subdural hematoma",
"     </li>",
"     <li>",
"      Communicating hydrocephalus",
"     </li>",
"     <li>",
"      Elevated intracranial pressure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relatively mild intensity and lack of autonomic symptoms readily differentiates hypnic headache from cluster. The duration and lack of autonomic features separate hypnic headache from the autonomic cephalalgias. The lack of more than one accompanying symptom",
"    <span class=\"nowrap\">",
"     (nausea/photophobia/phonophobia)",
"    </span>",
"    separates hypnic headaches from migraine.",
"   </p>",
"   <p>",
"    When recurrent headaches appear after the age of 50, neuroimaging of the brain should be considered to identify structural causes. Erythrocyte sedimentation rate and C-reactive protein testing should be obtained if there is any clinical suspicion of temporal arteritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34599?source=see_link\">",
"     \"Diagnosis of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of hypnic headache is not understood. The apparent cyclicity, the similar duration, and response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    suggest a pathophysiologic connection with cluster headache and hypothalamic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27174?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathophysiology of the trigeminal autonomic cephalalgias\", section on 'Hypothalamic activation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To test this hypothesis, a voxel based morphometric MRI study compared 14 patients with hypnic headache and 14 matched healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/10\">",
"     10",
"    </a>",
"    ]. Subjects with hypnic headache had reduced gray matter volume in the posterior hypothalamus. Ironically, an earlier report using similar methods found increased gray matter volume in a similar location among patients with cluster headache [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/11\">",
"     11",
"    </a>",
"    ]. Nevertheless, both studies implicate the posterior hypothalamus in headache disorders with a tendency toward cyclical and nocturnal occurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective treatments for hypnic headache in several case reports and small case series include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Caffeine in a tablet (40 to 60 mg) or beverage at bedtime [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       Indomethacin",
"      </a>",
"      50 mg three times daily [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      carbonate 300 to 600 mg daily [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/1,14\">",
"       1,14",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other medications that may be useful for hypnic headache include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      325 mg plus caffeine 40 mg at bedtime [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       Atenolol",
"      </a>",
"      25 mg at bedtime [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Belladonna 0.2 mg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      40 mg, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"       ergotamine",
"      </a>",
"      0.6 mg at bedtime [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34484?source=see_link\">",
"       Flunarizine",
"      </a>",
"      5 mg at bedtime [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/55/9077?source=see_link\">",
"       Frovatriptan",
"      </a>",
"      2.5 mg at bedtime [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       Lamotrigine",
"      </a>",
"      25 to 75 mg daily [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      25 mg daily for 15 days, then 12.5 mg daily for 15 days [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"       Sumatriptan",
"      </a>",
"      40 mg as acute therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       Topiramate",
"      </a>",
"      25 mg to 100 mg daily [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Melatonin 3 mg at bedtime [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sodium ferulate 75 to 300 mg daily in three divided doses [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5700/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypnic headache, also known as \"alarm clock headache\", occurs almost exclusively after the age of 40 to 50, and is characterized by episodes of dull head pain, often bilateral, that awaken the sufferer from sleep. Throbbing headache",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      migraine features are not uncommon. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with suspected hypnic headache, neuroimaging of the brain should be considered to rule out structural causes. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cause of hypnic headache is not understood, but the apparent cyclicity, the similar duration, and response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      suggest a pathophysiologic connection with cluster headache and hypothalamic dysfunction. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Limited evidence suggests that several treatments are effective for hypnic headache, including caffeine at bedtime,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      (50 mg three times daily), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      carbonate (300 to 600 mg daily). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5700/abstract/1\">",
"      Raskin NH. The hypnic headache syndrome. Headache 1988; 28:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5700/abstract/2\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5700/abstract/3\">",
"      Evers S, Goadsby PJ. Hypnic headache: clinical features, pathophysiology, and treatment. Neurology 2003; 60:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5700/abstract/4\">",
"      Liang JF, Fuh JL, Yu HY, et al. Clinical features, polysomnography and outcome in patients with hypnic headache. Cephalalgia 2008; 28:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5700/abstract/5\">",
"      Donnet A, Lant&eacute;ri-Minet M. A consecutive series of 22 cases of hypnic headache in France. Cephalalgia 2009; 29:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5700/abstract/6\">",
"      Rains JC, Poceta JS. Sleep-related headache syndromes. Semin Neurol 2005; 25:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5700/abstract/7\">",
"      Gould JD, Silberstein SD. Unilateral hypnic headache: a case study. Neurology 1997; 49:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5700/abstract/8\">",
"      Peatfield RC, Mendoza ND. Posterior fossa meningioma presenting as hypnic headache. Headache 2003; 43:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5700/abstract/9\">",
"      Mullally WJ, Hall KE. Hypnic headache secondary to haemangioblastoma of the cerebellum. Cephalalgia 2010; 30:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5700/abstract/10\">",
"      Holle D, Naegel S, Krebs S, et al. Hypothalamic gray matter volume loss in hypnic headache. Ann Neurol 2011; 69:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5700/abstract/11\">",
"      May A, Ashburner J, B&uuml;chel C, et al. Correlation between structural and functional changes in brain in an idiopathic headache syndrome. Nat Med 1999; 5:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5700/abstract/12\">",
"      Dodick DW, Mosek AC, Campbell JK. The hypnic (\"alarm clock\") headache syndrome. Cephalalgia 1998; 18:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5700/abstract/13\">",
"      Buzzi MG, Cologno D, Formisano R, Caltagirone C. Hypnic headache responsive to indomethacin: second Italian case. Funct Neurol 2005; 20:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5700/abstract/14\">",
"      Newman LC, Lipton RB, Solomon S. The hypnic headache syndrome: a benign headache disorder of the elderly. Neurology 1990; 40:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5700/abstract/15\">",
"      Morales-As&iacute;n F, Mauri JA, I&ntilde;iguez C, et al. The hypnic headache syndrome: report of three new cases. Cephalalgia 1998; 18:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5700/abstract/16\">",
"      Sch&uuml;rks M, Kastrup O, Diener HC. Triptan responsive hypnic headache? Eur J Neurol 2006; 13:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5700/abstract/17\">",
"      Ouahmane Y, Mounach J, Satte A, et al. Hypnic headache: response to lamotrigine in two cases. Cephalalgia 2012; 32:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5700/abstract/18\">",
"      Relja G, Zorzon M, Locatelli L, et al. Hypnic headache: rapid and long-lasting response to prednisone in two new cases. Cephalalgia 2002; 22:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5700/abstract/19\">",
"      Guido M, Specchio LM. Successful treatment of hypnic headache with topiramate: a case report. Headache 2006; 46:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5700/abstract/20\">",
"      Autunno M, Messina C, Blandino A, Rodolico C. Hypnic headache responsive to low-dose topiramate: a case report. Headache 2008; 48:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5700/abstract/21\">",
"      Dodick DW. Polysomnography in hypnic headache syndrome. Headache 2000; 40:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5700/abstract/22\">",
"      Peng H, Wang L, He B, et al. Hypnic headache responsive to sodium ferulate in 2 new cases. Clin J Pain 2013; 29:89.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3328 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-298F256B3B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_36_5700=[""].join("\n");
var outline_f5_36_5700=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34599?source=related_link\">",
"      Diagnosis of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16243?source=related_link\">",
"      Nummular headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27174?source=related_link\">",
"      Pathophysiology of the trigeminal autonomic cephalalgias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22101?source=related_link\">",
"      Primary cough headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44356?source=related_link\">",
"      Primary exertional headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16054?source=related_link\">",
"      Primary headache associated with sexual activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13714?source=related_link\">",
"      Primary stabbing headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12601?source=related_link\">",
"      Thunderclap headache",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_36_5701="Pulmonary edema PA";
var content_f5_36_5701=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cardiogenic pulmonary edema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pulmonary edema in a \"butterfly distribution\" due to left ventricular failure. Chest radiograph shows large perihilar opacities in patient with enlarged cardiac silhouette.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_36_5701=[""].join("\n");
var outline_f5_36_5701=null;
var title_f5_36_5702="Management of antiplatelet agents in patients undergoing endoscopic procedures";
var content_f5_36_5702=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of antiplatelet agents in patients undergoing endoscopic procedures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/36/5702/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/36/5702/contributors\">",
"     Patrick S Kamath, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/36/5702/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/36/5702/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/36/5702/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/36/5702/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/36/5702/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroenterologic procedures are commonly performed in patients taking antiplatelet agents. However, there are limited data assessing the bleeding risk of specific procedures in these settings.",
"   </p>",
"   <p>",
"    This topic will review the periprocedural management of patients taking antiplatelet agents. The management of patients taking anticoagulants, as well as patients with von Willebrand's disease, hemophilia, renal failure, liver failure, and thrombocytopenia are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21014?source=see_link\">",
"     \"Management of anticoagulants in patients undergoing endoscopic procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SOCIETY GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Society for Gastrointestinal Endoscopy (ASGE) has issued",
"    <a class=\"external\" href=\"file://www.asge.org/PublicationsProductsindex.aspx?id=352\">",
"     official guidelines",
"    </a>",
"    based upon the available evidence and consensus opinion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5702/abstract/1\">",
"     1",
"    </a>",
"    ]. The recommendations in this topic review are consistent with the ASGE guidelines. This topic is also addressed in reviews and guidelines from the American College of Gastroenterology, the American College of Chest Physicians, and the American College of Cardiology, which make similar recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5702/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PROCEDURE-RELATED BLEEDING RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, diagnostic endoscopic procedures are lower-risk for bleeding than are therapeutic procedures (",
"    <a class=\"graphic graphic_table graphicRef50700 \" href=\"UTD.htm?43/43/44731\">",
"     table 1",
"    </a>",
"    ). The procedure-related bleeding risk of various endoscopic procedures is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link&amp;anchor=H3#H3\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\", section on 'Procedure-related bleeding risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK OF THROMBOEMBOLIC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The probability of a thromboembolic complication following reversal or discontinuation of anticoagulation or antiplatelet agents depends upon the preexisting condition for which the medication was prescribed (",
"    <a class=\"graphic graphic_table graphicRef77634 \" href=\"UTD.htm?40/0/40971\">",
"     table 2",
"    </a>",
"    ). This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link&amp;anchor=H4#H4\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\", section on 'Risk of thromboembolic complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ELECTIVE PROCEDURES IN PATIENTS ON ANTIPLATELET AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiplatelet agents can be classified based on their mechanisms of action (",
"    <a class=\"graphic graphic_figure graphicRef75709 \" href=\"UTD.htm?28/48/29440\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      (acetylsalicylic acid) and related compounds (nonsteroidal antiinflammatory drugs and sulfinpyrazone) block cyclooxygenase, the enzyme that mediates the first step in prostaglandin and thromboxane biosynthesis from arachidonic acid.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       Dipyridamole",
"      </a>",
"      inhibits phosphodiesterase-mediated breakdown of cyclic AMP, which prevents platelet activation by multiple mechanisms.",
"     </li>",
"     <li>",
"      Thienopyridines (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ) achieve their antiplatelet effect by blocking the binding of ADP to a specific platelet receptor (P2Y12), inhibiting adenylyl cyclase and platelet aggregation [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5702/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Glycoprotein",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      antibodies and receptor antagonists (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      , roxifiban,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"       eptifibatide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"       tirofiban",
"      </a>",
"      , orbofiban, sibrafiban) inhibit the final common pathway of platelet aggregation and may also prevent initial adhesion to the vessel wall.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Aspirin and NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    and other nonsteroidal antiinflammatory drugs (NSAIDs) given alone in standard doses do not appear to increase the risk of significant bleeding after upper endoscopy with biopsy, colonoscopy with biopsy, or biliary sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5702/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. However, data are conflicting regarding whether there is an increased risk of postpolypectomy bleeding in patients taking aspirin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    NSAIDs. In a preliminary report of a retrospective study of 3191 colonoscopies with polypectomy, patients who received both aspirin and another NSAID had an increased risk of immediate post-polypectomy bleeding compared with those who did not (odds ratio 14) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5702/abstract/10\">",
"     10",
"    </a>",
"    ]. However, a subsequent study of 1174 patients who underwent polypectomy found no difference in postpolypectomy bleeding rates among those who received aspirin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an NSAID and those who did not (3.2 versus 3.0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5702/abstract/11\">",
"     11",
"    </a>",
"    ]. While it is unclear if aspirin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    NSAID increase postpolypectomy bleeding, the combination of aspirin or other NSAIDS with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    may increase the risk of postpolypectomy bleeding. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Thienopyridines (ticlopidine, clopidogrel)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    and NSAIDS do",
"    <strong>",
"     not",
"    </strong>",
"    need to be discontinued for endoscopic procedures. However, for patients undergoing high-risk procedures (",
"    <a class=\"graphic graphic_table graphicRef50700 \" href=\"UTD.htm?43/43/44731\">",
"     table 1",
"    </a>",
"    ), some clinicians elect to stop aspirin and NSAIDs five to seven days prior to the procedure, taking into account the underlying indication for the antiplatelet therapy. In addition, if patients are on aspirin combined with another NSAID, it may be prudent to hold the NSAID if possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dipyridamole",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of a preexisting bleeding disorder, endoscopic procedures may be performed in patients who take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    or combination dipyridamole-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in standard doses (",
"    <a class=\"graphic graphic_table graphicRef64448 \" href=\"UTD.htm?18/5/18524\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5702/abstract/12\">",
"     12",
"    </a>",
"    ]. However, the safety in patients undergoing high-risk procedures is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Thienopyridines (ticlopidine, clopidogrel)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to discontinue a thienopyridine before endoscopy should take into account the potential risk of stopping the medication and consultation with the patient's cardiologist or neurologist should be considered before stopping these agents.",
"   </p>",
"   <p>",
"    Thienopyridines are frequently used in combination with other antiplatelet agents. Dual antiplatelet therapy (DAT) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a thienopyridine (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) is used in the treatment of patients with vascular stents, acute coronary syndromes, and cerebrovascular disease. DAT is especially important in patients with drug-eluting cardiac stents, since drug-eluting stents have an increased risk of thrombosis compared to non-drug-eluting stents.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link\">",
"       \"Antiplatelet therapy after coronary artery stenting\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link\">",
"       \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link\">",
"       \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link\">",
"       \"Antiplatelet therapy for secondary prevention of stroke\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link\">",
"       \"Antithrombotic therapy for percutaneous coronary intervention: General use\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, some studies suggest that the use of DAT may increase the risk of upper gastrointestinal bleeding and post-polypectomy bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5702/abstract/3,10,13\">",
"     3,10,13",
"    </a>",
"    ]. In a study of 147 patients undergoing polypectomy, the rate of postpolypectomy bleeding was higher in the group receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    compared with those who did not (4 versus 1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5702/abstract/13\">",
"     13",
"    </a>",
"    ]. On multivariable analysis, the combination of clopidogrel and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or another NSAID (but not clopidogrel alone) was associated with an increased risk of postpolypectomy bleeding (OR 1.3).",
"   </p>",
"   <p>",
"    However, a more recent study found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    use was not associated with an increased risk of postpolypectomy bleeding. The study included 118 patients who were receiving clopidogrel with 1849 patients who were not. Of the patients on clopidogrel, 79 percent were also taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5702/abstract/14\">",
"     14",
"    </a>",
"    ]. Postpolypectomy bleeding occurred in one patient in the clopidogrel group (0.9 percent) and in six patients in the control group (0.3 percent; p = 0.4).",
"   </p>",
"   <p>",
"    Thienopyridines do",
"    <strong>",
"     not",
"    </strong>",
"    need to be discontinued for low-risk procedures (",
"    <a class=\"graphic graphic_table graphicRef50700 \" href=\"UTD.htm?43/43/44731\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64448 \" href=\"UTD.htm?18/5/18524\">",
"     table 3",
"    </a>",
"    ). For high-risk procedures in patients with low thromboembolic risk (",
"    <a class=\"graphic graphic_table graphicRef77634 \" href=\"UTD.htm?40/0/40971\">",
"     table 2",
"    </a>",
"    ), thienopyridines should be discontinued 7 to 10 days prior to the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link&amp;anchor=H4#H4\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\", section on 'Risk of thromboembolic complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Discontinuing thienopyridines should also be considered in patients at high risk for thromboembolic complications who are undergoing high-risk procedures if the risk of bleeding is thought to outweigh the risk of thromboembolism. Patients who are taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    should continue to do so. For patients not on aspirin, the addition of aspirin during the periendoscopic period may decrease the risk of thromboembolic events [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5702/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with cardiac stents, the American Society of Gastrointestinal Endoscopy guidelines recommend avoiding procedures until the patient has received antithrombotic therapy for the minimum recommended duration based upon current guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5702/abstract/1\">",
"     1",
"    </a>",
"    ]. Once beyond that period, they recommend stopping the thienopyridine 7 to 10 days prior to the procedure, while continuing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . This issue is also discussed in guidelines from the American College of Chest Physicians for patients undergoing surgical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5702/abstract/4\">",
"     4",
"    </a>",
"    ]. The guidelines recommend that patients who are within six weeks of bare-metal stent placement or within six months of drug-eluting stent placement have surgical procedures deferred, when possible, until after six weeks and six months of placement, respectively. However, if the procedure must be done, then they recommend continuing the thienopyridine and aspirin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link\">",
"     \"Antiplatelet therapy after coronary artery stenting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following the procedure, the thienopyridine should be restarted, with or without a loading dose, as soon as it is deemed safe, taking into account the patient's indication for taking it and any therapy performed during the endoscopy that may increase the risk for bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5702/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     URGENT PROCEDURES IN PATIENTS ON ANTIPLATELET AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data regarding the management of patients on antiplatelet agents for acute coronary syndromes or a recently placed vascular stent who need urgent endoscopy (",
"    <a class=\"graphic graphic_table graphicRef64448 \" href=\"UTD.htm?18/5/18524\">",
"     table 3",
"    </a>",
"    ). The ASGE guidelines suggest holding antiplatelet agents until hemostasis has been achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5702/abstract/1\">",
"     1",
"    </a>",
"    ]. In cases of life-threatening or serious bleeding, platelet transfusion may be required. If time allows a cardiology consult should be obtained to assist with management of the antiplatelet agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of bleeding from endoscopic procedures can be classified as high or low. In general, diagnostic procedures are low-risk, whereas therapeutic procedures are high-risk (",
"      <a class=\"graphic graphic_table graphicRef50700 \" href=\"UTD.htm?43/43/44731\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link&amp;anchor=H3#H3\">",
"       \"Endoscopic procedures in patients with disorders of hemostasis\", section on 'Procedure-related bleeding risk'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The probability of a thromboembolic complication following reversal or discontinuation of anticoagulation or antiplatelet agents depends upon the preexisting condition for which the medication was prescribed (",
"      <a class=\"graphic graphic_table graphicRef77634 \" href=\"UTD.htm?40/0/40971\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link&amp;anchor=H4#H4\">",
"       \"Endoscopic procedures in patients with disorders of hemostasis\", section on 'Risk of thromboembolic complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and other nonsteroidal antiinflammatory drugs (NSAIDs) given alone and in standard doses be continued for elective endoscopic procedures (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Aspirin and NSAIDs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision regarding whether a thienopyridine (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ) should be discontinued before endoscopy should be weighed against the potential risk of a thromboembolic complication. We suggest consultation with a cardiologist or neurologist (depending on the indication for the medication) prior to discontinuing it. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Thienopyridines (ticlopidine, clopidogrel)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a thienopyridine (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ) is going to be held for a procedure, it should be stopped 7 to 10 days prior to the procedure.",
"     </li>",
"     <li>",
"      For patients on dual antiplatelet therapy with a thienopyridine and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      undergoing high-risk procedures, if the thienopyridine is going to be held, we suggest continuing the patient on aspirin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Thienopyridines (ticlopidine, clopidogrel)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following the procedure, the thienopyridine should be restarted as soon as it is deemed safe, taking into account the patient's indication for taking it and any therapy performed during the endoscopy that may increase the risk for bleeding. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Thienopyridines (ticlopidine, clopidogrel)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of patients taking anticoagulants is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21014?source=see_link\">",
"       \"Management of anticoagulants in patients undergoing endoscopic procedures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other disorders of hemostasis that may require treatment prior to gastrointestinal procedures, including von Willebrand's disease, hemophilia A and B, renal failure, liver failure, and thrombocytopenia, are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link\">",
"       \"Endoscopic procedures in patients with disorders of hemostasis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5702/abstract/1\">",
"      ASGE Standards of Practice Committee, Anderson MA, Ben-Menachem T, et al. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc 2009; 70:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5702/abstract/2\">",
"      Kwok A, Faigel DO. Management of anticoagulation before and after gastrointestinal endoscopy. Am J Gastroenterol 2009; 104:3085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5702/abstract/3\">",
"      Becker RC, Scheiman J, Dauerman HL, et al. Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. J Am Coll Cardiol 2009; 54:2261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5702/abstract/4\">",
"      Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e326S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5702/abstract/5\">",
"      Foster CJ, Prosser DM, Agans JM, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001; 107:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5702/abstract/6\">",
"      Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5702/abstract/7\">",
"      Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5702/abstract/8\">",
"      Shiffman ML, Farrel MT, Yee YS. Risk of bleeding after endoscopic biopsy or polypectomy in patients taking aspirin or other NSAIDS. Gastrointest Endosc 1994; 40:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5702/abstract/9\">",
"      Hussain N, Alsulaiman R, Burtin P, et al. The safety of endoscopic sphincterotomy in patients receiving antiplatelet agents: a case-control study. Aliment Pharmacol Ther 2007; 25:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5702/abstract/10\">",
"      Grossman EB, Maranino AN, Zamora DC, et al. Antiplatelet medications increase the risk of post-polypectomy bleeding. Gastrointest Endosc 2010; 71:AB138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5702/abstract/11\">",
"      Manocha D, Singh M, Mehta N, Murthy UK. Bleeding risk after invasive procedures in aspirin/NSAID users: polypectomy study in veterans. Am J Med 2012; 125:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5702/abstract/12\">",
"      Zuckerman MJ, Hirota WK, Adler DG, et al. ASGE guideline: the management of low-molecular-weight heparin and nonaspirin antiplatelet agents for endoscopic procedures. Gastrointest Endosc 2005; 61:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5702/abstract/13\">",
"      Singh M, Mehta N, Murthy UK, et al. Postpolypectomy bleeding in patients undergoing colonoscopy on uninterrupted clopidogrel therapy. Gastrointest Endosc 2010; 71:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5702/abstract/14\">",
"      Feagins LA, Uddin FS, Davila RE, et al. The rate of post-polypectomy bleeding for patients on uninterrupted clopidogrel therapy during elective colonoscopy is acceptably low. Dig Dis Sci 2011; 56:2631.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2632 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_36_5702=[""].join("\n");
var outline_f5_36_5702=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SOCIETY GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PROCEDURE-RELATED BLEEDING RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK OF THROMBOEMBOLIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ELECTIVE PROCEDURES IN PATIENTS ON ANTIPLATELET AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Aspirin and NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dipyridamole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Thienopyridines (ticlopidine, clopidogrel)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      URGENT PROCEDURES IN PATIENTS ON ANTIPLATELET AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2632\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2632|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/48/29440\" title=\"figure 1\">",
"      Mechanism antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2632|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/43/44731\" title=\"table 1\">",
"      Bleeding risk GI procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/0/40971\" title=\"table 2\">",
"      Risk GI procedure conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/5/18524\" title=\"table 3\">",
"      Newer antiplatelet ASGE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=related_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21014?source=related_link\">",
"      Management of anticoagulants in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_36_5703="NSAIDs: Therapeutic use and variability of response in adults";
var content_f5_36_5703=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   NSAIDs: Therapeutic use and variability of response in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/36/5703/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/36/5703/contributors\">",
"     Daniel H Solomon, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/36/5703/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/36/5703/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/36/5703/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/36/5703/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/36/5703/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of nonsteroidal antiinflammatory drugs (NSAIDs) are readily available (at least 20 in the United States and more elsewhere) and are widely used throughout the world (",
"    <a class=\"graphic graphic_table graphicRef70067 \" href=\"UTD.htm?23/54/24431\">",
"     table 1",
"    </a>",
"    ). In the United States,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/36/43592?source=see_link\">",
"     ketoprofen",
"    </a>",
"    can also be obtained without prescription. Each year, approximately 60 million NSAID prescriptions are written, with the number of prescriptions for older patients approximately 3.6-fold higher than that for younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5703/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Questions concerning the variability of response to the effects of the different NSAIDs have led to efforts to understand the potential and real differences between these drugs. All NSAIDs appear to be absorbed completely, have negligible first pass hepatic metabolism, are tightly bound to albumin, and have small volumes of distribution. Patients with hypoalbuminemia may, therefore, have higher free serum concentrations of drug.",
"   </p>",
"   <p>",
"    However, it is unclear whether the blood level of a NSAID is important in assessing its mode of action or its effectiveness, since protein-binding is saturable in the normal dose range for several NSAIDs. As a result, increases in dose may not lead to increases in steady state concentration of the drug. At equipotent doses, the clinical efficacy of the various NSAIDs in patient populations is similar [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5703/abstract/3\">",
"     3",
"    </a>",
"    ]; in contrast, individual responses are highly variable [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5703/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of the observed individual differences with specific NSAIDs are particularly evident with respect to toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5703/abstract/3\">",
"     3",
"    </a>",
"    ]. As an example, it is not unusual for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    to induce headaches after a single dose in some patients. More commonly, individual patients have more symptoms or signs of gastrointestinal toxicity with one NSAID than with another [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5703/abstract/5\">",
"     5",
"    </a>",
"    ]. Some differences in toxicity may be explained by variations in absorption, distribution, and metabolism. Differences in the mode of action may be important as well.",
"   </p>",
"   <p>",
"    This topic will review the issues surrounding the differences in response to the various NSAIDs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5703/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. Clinical considerations in the use of these agents will also be discussed, while the different types of toxicity that may be seen with both nonselective and COX-2 selective NSAIDs are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HYPOTHESES CONCERNING VARIABILITY OF RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differences in the effects of the various NSAIDs have been ascribed to variations in one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mechanism of action. Some NSAIDs are more potent inhibitors of prostaglandin synthesis, while others are more effective in altering other nonprostaglandin mediated biologic events.",
"     </li>",
"     <li>",
"      Enantiomeric state",
"     </li>",
"     <li>",
"      Pharmacokinetics, pharmacodynamics, or metabolism",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both prostaglandin-mediated and nonprostaglandin-mediated mechanisms of action contribute to NSAID function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Prostaglandin-mediated",
"    </span>",
"    &nbsp;&mdash;&nbsp;The six major classes of NSAIDs all have the common property of inhibiting cyclooxygenase, the enzyme which catalyzes the synthesis of cyclic endoperoxidases from arachidonic acid to form prostaglandins. Different NSAIDs have varying inhibitory potentials of the two known isoforms of cyclooxygenase, COX-1 and COX-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5703/abstract/7-12\">",
"     7-12",
"    </a>",
"    ]. Unfortunately, there is a paucity of data correlating the degree and type of cyclooxygenase inhibition with antiinflammatory efficacy in individual patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5703/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. An exception is the COX-2 specific inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1336?source=see_link\">",
"     \"NSAIDs: Mechanism of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The nonacetylated salicylates (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5350?source=see_link\">",
"     salsalate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/43/42677?source=see_link\">",
"     choline magnesium trisalicylate",
"    </a>",
"    ) are weak inhibitors of cyclooxygenase, but some studies suggest that they are similar in clinically efficacy to the nonsalicylated NSAIDs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5703/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variabilities in response to NSAIDs may also result from alterations in some prostaglandin effects that have been recognized more recently than the initial observations regarding cyclooxygenase inhibition. As an example, prostaglandins have been demonstrated to be important inhibitors of apoptosis in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5703/abstract/15\">",
"     15",
"    </a>",
"    ]. NSAID administration may reestablish the return to a more normal cell cycle via inhibition of prostaglandins, a pathway that may be significant in the downregulation of diseases driven by immunologically-based functions. Additionally, many human genes are involved in COX-1 and COX-2 metabolism. In healthy volunteers, metabolism of selective COX-2 inhibitors varies significantly between individuals, suggesting further potential explanations for variability in response [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5703/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Nonprostaglandin-mediated",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several nonprostaglandin-mediated NSAID-induced mechanisms of action may also be important in determining a patient's responsiveness to these agents. These mechanisms are generally related to the ability of NSAIDs to insert into biological membranes and disrupt a wide range of cell function and cell to cell interactions. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NSAIDs interfere with neutrophil-endothelial cell adherence by decreasing the availability of L-selectins, thereby removing a critical step in the migration of granulocytes to sites of inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5703/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      NSAIDs inhibit nuclear factor kappa B (NF-kB) dependent transcription in vitro, resulting in a decrease in available nitric oxide synthetase [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5703/abstract/18\">",
"       18",
"      </a>",
"      ]. Once induced by cytokines and other proinflammatory mediators, nitric oxide synthetase produces nitric oxide in large amounts, thereby causing vasodilation, cytotoxicity, and increased vascular permeability [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5703/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The antinociceptive actions of some NSAIDs, but not all, appear to involve the L-arginine-NO-cyclic GMP-potassium channel pathways [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5703/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role and importance of these nonprostaglandin-mediated processes in clinical inflammation is unclear. It is also unknown if any of these potential mechanisms of action explain the variation in individual patient response to NSAIDs and possibly the occurrence of adverse events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical studies have attempted to isolate the mechanisms underlying the origin of this variation in response by assessing disease activity during therapy with each NSAID and by correlating these results with multiple biochemical measurements. Such measurements include serum levels of tumor necrosis factor-alpha (TNFa), interleukin-6 (IL-6), the erythrocyte sedimentation rate, C-reactive protein, IL-1 receptors, hematocrit, and the white blood cell count.",
"   </p>",
"   <p>",
"    Intriguing data suggest that differences in measurable biologic responses may result in part from differences in drug pharmacodynamics. As an example, one study used a 2x2 factorial design to sequentially expose patients with either osteoarthritis (OA) or rheumatoid arthritis (RA) to two NSAIDs from two different classes:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/25/9625?source=see_link\">",
"     piroxicam",
"    </a>",
"    (an oxicam) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/36/43592?source=see_link\">",
"     ketoprofen",
"    </a>",
"    (a phenylpropionic acid derivative) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5703/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients were initially treated with one of the drugs for two weeks and were then switched to the other for another two week period. A number of clinical and biochemical responses were measured, and the following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pharmacodynamics of the individual NSAIDs, including their biochemical and physiological effects and their mechanisms of action, may be very important in predicting the ultimate response. By comparison, pharmacokinetic differences across NSAIDs, including differences in absorption, distribution, and differential metabolism, are probably not significant.",
"     </li>",
"     <li>",
"      No clear pattern of effect could be associated with the serum concentrations of either NSAID.",
"     </li>",
"     <li>",
"      Both the changes in and the absolute serum concentrations of cytokines may not be as significant as the changes in tissue levels.",
"     </li>",
"     <li>",
"      The enantiomeric state of the drugs was unimportant in determining differences in response.",
"     </li>",
"     <li>",
"      Differences in effects were not due to fluctuations in disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ISSUES IN THE THERAPEUTIC USE OF NSAIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for and efficacy of NSAIDs vary by patient and disease. Discussions of the use of these drugs in specific disorders are presented in the appropriate topic reviews. The following discussion is a general guide to the administration of NSAIDs.",
"   </p>",
"   <p>",
"    Observed variations in patient response may result in part from the pharmacodynamics of a particular drug. Thus, it is believed that, if a patient fails an NSAID of one class, the substitution of an NSAID of a different class is a reasonable therapeutic option. Each attempt to achieve a response should probably last for about two weeks. The NSAID dose should be at the maximal antiinflammatory range. This strategy has never been evaluated in a prospective well-controlled study.",
"   </p>",
"   <p>",
"    Unfortunately, the same approach is not necessarily applicable to patients who develop a toxic effect with one NSAID. Some toxicities are unique to particular classes of NSAIDs, while others are related to the general mode of action of inhibition of prostaglandin synthesis. One such example is acute renal failure due to renal vasoconstriction, which is mediated by decreased production of vasodilator prostaglandins and may be similar across agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dosing regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies suggest that compliance with specific medications is enhanced when dosed less frequently. Studies supporting this view have frequently been performed in asymptomatic hypertensive patients. Such patients may be more likely to comply with a once daily regimen than with a more demanding regimen. In comparison, patients in chronic discomfort may be more compliant with a regimen that alleviates their discomfort, independent of dose schedule (but within limits). If the drug is adequately analgesic, it is more likely that patients will take drugs more frequently than once daily. Unfortunately, patient preference for specific NSAID dosing regimens has not been well-studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Nonanalgesic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the nonsalicylate, non-COX-2 selective NSAIDs and acetylsalicylic acid (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) inhibit platelet aggregation via inhibition of platelet COX-1 activity. However, aspirin inhibits platelet COX-1 in an irreversible manner and, thus, has proven benefits in reducing the risk of secondary thrombotic cardiovascular events. These properties may be important enough to warrant its continued use in the patient who also needs a typical NSAID. Thus, if clinically required, such patients can be continued on low-dose aspirin. Administration of some NSAIDs may interfere with desirable antiplatelet effects of aspirin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5703/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAIDs can interact with numerous drugs. These include anticoagulants, antiplatelet agents, antihypertensives, calcineurin inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , diuretics, glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , selective serotonin reuptake inhibitors (SSRIs),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX), and other medications. Potential drug interactions with NSAIDs are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1336?source=see_link&amp;anchor=H8064004#H8064004\">",
"     \"NSAIDs: Mechanism of action\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interactions may occur due to NSAID-related reduction in renal perfusion or additive hemorrhagic toxicity. Furthermore, some NSAIDs modestly inhibit CYP-2C9 (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/36/43592?source=see_link\">",
"     ketoprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/42/33440?source=see_link\">",
"     flurbiprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/38/35432?source=see_link\">",
"     meloxicam",
"    </a>",
"    ) or",
"    <span class=\"nowrap\">",
"     CYP-2C8/2D6",
"    </span>",
"    (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    )",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glucuronidation, which may increase concentrations of drugs highly dependent on these pathways for clearance. (See Lexi-Interact&trade; program included with UpToDate to obtain additional information, including suggestions for management, and to check for other potential interactions.)",
"   </p>",
"   <p>",
"    Interference with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    's antiplatelet effects has been noted in ex vivo studies of healthy control subjects receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    prior to aspirin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5703/abstract/22\">",
"     22",
"    </a>",
"    ]. However, ex vivo platelet assays may not accurately reflect in vivo conditions, and the clinical relevance of such NSAID-aspirin interactions remains to be determined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, NSAIDs are safe drugs when used in patients who are not at high risk for gastrointestinal, renal, or cardiovascular reactions. Nevertheless, it is very important to take a careful history to avoid an unfortunate surprise. A good clinician evaluation will often highlight these risks, and appropriate action should then be taken to minimize the likelihood of a poor outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many of the toxic effects of the NSAIDs are related to their main mode of action, the inhibition of prostaglandin synthesis. However, this issue has become more complex with the availability of selective COX-2 inhibitors, which have a lower rate of some toxicities, particularly gastrointestinal, and possibly a higher rate of cardiovascular adverse events. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10375?source=see_link\">",
"     \"COX-2 inhibitors and gastroduodenal toxicity &mdash; major clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is, therefore, difficult to identify the &ldquo;safest&rdquo; NSAID. Many clinicians believe that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    is quite safe, which is true when the drug is given at the lowest possible dose. However, increasing doses of any NSAID is associated with an increased risk of a toxic event. A selective COX-2 inhibitor, or co-prescription of a PPI,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    , or high dose H2RA, may be preferred if gastrointestinal toxicity is an issue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12147968\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At equipotent doses, the efficacy of the various NSAIDs in patient populations is similar, although individual responses are highly variable. Some of the observed differences between individual NSAIDs are particularly evident with respect to toxicity. The differences in the effects of the various NSAIDs have been ascribed to variations in mechanism of action, enantiomeric state, pharmacokinetics, pharmacodynamics, or metabolism. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Hypotheses concerning variability of response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some NSAIDs are more potent inhibitors of prostaglandin synthesis, while others are more effective in altering other nonprostaglandin mediated biologic events. Different NSAIDs have varying inhibitory potential of the two known isoforms of cyclooxygenase, COX-1 and COX-2. Except for COX-2 inhibitors, there is a paucity of data correlating the degree and type of cyclooxygenase inhibition with antiinflammatory efficacy in individual patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of action'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Prostaglandin-mediated'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several nonprostaglandin-mediated NSAID-induced mechanisms of action may also be important in determining a patient's responsiveness to these agents. These mechanisms are generally related to the ability of NSAIDs to insert into biological membranes and disrupt a wide range of cell function and cell to cell interactions. The role and importance of these processes in clinical inflammation is unclear. It is also unknown if any of these potential mechanisms of action explain the variation in individual patient response to NSAIDs. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Nonprostaglandin-mediated'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Observed variations in patient response may result, in part, from the pharmacodynamics of a particular drug. Thus, if a patient fails an NSAID of one class, the substitution of an NSAID of a different class is a reasonable therapeutic option. Each attempt to achieve a response should use a dose at the maximal antiinflammatory range and last for about two weeks. By contrast, pharmacokinetic effects, including absorption, distribution, and differential metabolism, are probably not significant factors. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unlike efficacy, some toxicities are unique to particular classes of NSAIDs, while others are related to the general mode of action of inhibition of prostaglandin synthesis. As an example, acute renal failure due to renal vasoconstriction, which is mediated by decreased production of vasodilator prostaglandins, may be equally likely with any agent. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Issues in the therapeutic use of NSAIDs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both nonselective NSAIDs and acetylsalicylic acid (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ) inhibit platelet aggregation via inhibition of platelet COX-1 activity. However, aspirin inhibits platelet COX-1 in an irreversible manner, unlike the reversible inhibition of the nonselective nonsalicylate NSAIDs, and has proven benefits in reducing the risk of secondary thrombotic cardiovascular events. Thus, aspirin may also be used for nonanalgesic effects. In some patients, coadministration of aspirin and another NSAID may be appropriate, but it is associated with an increased risk of GI bleeding. Some NSAIDs, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      , may interfere with desirable antiplatelet effects of aspirin; timing of administration may be an important factor. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Nonanalgesic effects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of drug interactions are of note. Since all NSAIDs but ASA are highly protein bound, interactions between NSAIDs and other highly protein bound drugs may be clinically important. For example, NSAIDs may cause displacement of protein bound",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , resulting in an increased biologic effect when they are concurrently prescribed with a NSAID. Similarly, NSAIDs may increase the INR in patients receiving warfarin, particularly with the initiation of simultaneous therapy, adding to the anticoagulant effect of NSAID-induced platelet dysfunction. Renal effects of NSAIDs may cause small decreases in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      clearance and clinically significant reductions in renal function in patients receiving concomitant therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, NSAIDs are safe for patients who are not at high risk for gastrointestinal, renal, or cardiovascular reactions. It is important to perform a careful evaluation to identify such risks. Selective COX-2 inhibitors, which have lower rates of some toxicities, particularly gastrointestinal, can exhibit a higher rate of cardiovascular adverse events compared with nonselective NSAIDs. It is, therefore, difficult to identify the &ldquo;safest&rdquo; NSAID. Increasing doses of any NSAID is associated with an increased risk of a toxic event. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Toxicity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5703/abstract/1\">",
"      Baum C, Kennedy DL, Forbes MB. Utilization of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1985; 28:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5703/abstract/2\">",
"      Hamerman D. Clinical implications of osteoarthritis and ageing. Ann Rheum Dis 1995; 54:82.",
"     </a>",
"    </li>",
"    <li>",
"     Agency for Healthcare Research and Quality. Comparative Effectiveness Review Number 38. Analgesics for osteoarthritis: An update of the 2006 comparative effectiveness review. Executive summary. www.effectivehealthcare.ahrq.gov/ehc/products/180/805/Analgesics-Update_executive-summary_20111007.pdf (Accessed on March 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5703/abstract/4\">",
"      Furst DE. Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs. Arthritis Rheum 1994; 37:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5703/abstract/5\">",
"      Heymann MA. Non-narcotic analgesics. Use in pregnancy and fetal and perinatal effects. Drugs 1986; 32 Suppl 4:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5703/abstract/6\">",
"      Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs--differences and similarities. N Engl J Med 1991; 324:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5703/abstract/7\">",
"      Bradley JD, Brandt KD, Katz BP, et al. Treatment of knee osteoarthritis: relationship of clinical features of joint inflammation to the response to a nonsteroidal antiinflammatory drug or pure analgesic. J Rheumatol 1992; 19:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5703/abstract/8\">",
"      Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268:6610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5703/abstract/9\">",
"      Cush JJ, Jasin HE, Johnson R, Lipsky PE. Relationship between clinical efficacy and laboratory correlates of inflammatory and immunologic activity in rheumatoid arthritis patients treated with nonsteroidal antiinflammatory drugs. Arthritis Rheum 1990; 33:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5703/abstract/10\">",
"      Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A 1992; 89:7384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5703/abstract/11\">",
"      Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A 1993; 90:11693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5703/abstract/12\">",
"      Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994; 271:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5703/abstract/13\">",
"      Bombardier C, Peloso PM, Goldsmith CH. Salsalate, a nonacetylated salicylate, is as efficacious as diclofenac in patients with rheumatoid arthritis. Salsalate-Diclofenac Study Group. J Rheumatol 1995; 22:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5703/abstract/14\">",
"      Does the acetyl group of aspirin contribute to the antiinflammatory efficacy of salicylic acid in the treatment of rheumatoid arthritis? The Multicenter Salsalate/Aspirin Comparison Study Group. J Rheumatol 1989; 16:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5703/abstract/15\">",
"      Lu X, Xie W, Reed D, et al. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. Proc Natl Acad Sci U S A 1995; 92:7961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5703/abstract/16\">",
"      Fries S, Grosser T, Price TS, et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 2006; 130:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5703/abstract/17\">",
"      D&iacute;az-Gonz&aacute;lez F, Gonz&aacute;lez-Alvaro I, Campanero MR, et al. Prevention of in vitro neutrophil-endothelial attachment through shedding of L-selectin by nonsteroidal antiinflammatory drugs. J Clin Invest 1995; 95:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5703/abstract/18\">",
"      Amin AR, Vyas P, Attur M, et al. The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase. Proc Natl Acad Sci U S A 1995; 92:7926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5703/abstract/19\">",
"      Hawkey CJ. Future treatments for arthritis: new NSAIDs, NO NSAIDs, or no NSAIDs? Gastroenterology 1995; 109:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5703/abstract/20\">",
"      Ortiz MI, Granados-Soto V, Casta&ntilde;eda-Hern&aacute;ndez G. The NO-cGMP-K+ channel pathway participates in the antinociceptive effect of diclofenac, but not of indomethacin. Pharmacol Biochem Behav 2003; 76:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5703/abstract/21\">",
"      Walker JS, Sheather-Reid RB, Carmody JJ, et al. Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis: support for the concept of \"responders\" and \"nonresponders\". Arthritis Rheum 1997; 40:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5703/abstract/22\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345:1809.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7993 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-CDD449C725-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_36_5703=[""].join("\n");
var outline_f5_36_5703=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12147968\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HYPOTHESES CONCERNING VARIABILITY OF RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Prostaglandin-mediated",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Nonprostaglandin-mediated",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ISSUES IN THE THERAPEUTIC USE OF NSAIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dosing regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Nonanalgesic effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12147968\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7993\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7993|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/54/24431\" title=\"table 1\">",
"      Nonopioid analgesic and NSAID table",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10375?source=related_link\">",
"      COX-2 inhibitors and gastroduodenal toxicity &mdash; major clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1336?source=related_link\">",
"      NSAIDs: Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_36_5704="Normal coronary artery OCT";
var content_f5_36_5704=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Normal coronary artery as visualized by intracoronary OCT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Cross sectional view of the coronary artery. The coronary lumen is signal-poor and black, whereas the vessel is visualized using sepia false color scale. The normal artery wall shows three-layer appearance. (IC) OCT imaging catheter in the center of the lumen; asterisk indicates the angioplasty guide wire artefact.",
"    <br>",
"     (B) Magnification (2.8x) showing three layer appearance of the normal vessel wall corresponding to the intma (I) which appears signal rich, bright yellow; the media (M) which appears signal-poor, dark and the adventitia (A) which appears signal-rich, bright yellow, peri-adventitial tissue is visible (PAT).",
"     <div class=\"footnotes\">",
"      OCT: St. Jude/Lightlab Imaging C7XR.",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Dr. Evelyn Regar, Thoraxcenter.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_36_5704=[""].join("\n");
var outline_f5_36_5704=null;
var title_f5_36_5705="Lead nephropathy and lead-related nephrotoxicity";
var content_f5_36_5705=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lead nephropathy and lead-related nephrotoxicity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/36/5705/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/36/5705/contributors\">",
"     Virginia M Weaver, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/36/5705/contributors\">",
"     Bernard G Jaar, MD, MPH, FASN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/36/5705/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/36/5705/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/36/5705/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/36/5705/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/36/5705/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic lead exposure can affect a variety of organ systems, including the kidney where it can produce lead nephropathy, a chronic interstitial nephritis. The high level of lead exposure required to cause lead nephropathy is now increasingly rare, particularly in developed countries, due to occupational controls and removal of lead from paint, gasoline, and other environmental sources (",
"    <a class=\"graphic graphic_figure graphicRef60319 \" href=\"UTD.htm?24/52/25422\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, prolonged lead exposure at the lower levels currently encountered in developed countries may still contribute to renal toxicity, an association that has been referred to as lead-related nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/1\">",
"     1",
"    </a>",
"    ]. This is most likely to occur in patients who have chronic kidney disease or are at risk because of diabetes mellitus or hypertension.",
"   </p>",
"   <p>",
"    The impact of chronic lead exposure on the kidney will be reviewed here. Other clinical manifestations of lead poisoning, as well as the evaluation and management of lead poisoning in adults and children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link\">",
"     \"Adult lead poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link\">",
"     \"Childhood lead poisoning: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SOURCES OF LEAD EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of current sources of lead exposure, which is primarily related to occupational exposures in adults and to ingestion or inhalation of environmental lead in adults and children (",
"    <a class=\"graphic graphic_table graphicRef62969 \" href=\"UTD.htm?30/45/31453\">",
"     table 1",
"    </a>",
"    ). In addition, since lead accumulates in bone, the body lead burden from past exposures also contributes to current exposure.",
"   </p>",
"   <p>",
"    Exposure sources are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link&amp;anchor=H3#H3\">",
"     \"Adult lead poisoning\", section on 'Sources of exposure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11001?source=see_link&amp;anchor=H2#H2\">",
"     \"Childhood lead poisoning: Exposure and prevention\", section on 'Exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF LEAD DOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood lead is a short-term measurement, with a half-life of about 30 days, that reflects both exposure from current exogenous sources and the release of endogenous lead from bone and soft tissue stores [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blood lead data from the National Health and Nutrition Examination Survey (NHANES) II, obtained between 1976 and 1980 during the phase-out of leaded gasoline in the United States, showed that lead exposure was significant and widespread [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/4\">",
"     4",
"    </a>",
"    ]. The removal of lead from gasoline (",
"    <a class=\"graphic graphic_figure graphicRef60319 \" href=\"UTD.htm?24/52/25422\">",
"     figure 1",
"    </a>",
"    ) resulted in substantial reductions in lead exposure. Geometric mean blood lead levels in adults in the United States fell from 15.8 and 11.0",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.76 and 0.53",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in men and women, respectively, in NHANES II [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/4\">",
"     4",
"    </a>",
"    ], to 1.38",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.067",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in NHANES data from 2007 and 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/5\">",
"     5",
"    </a>",
"    ]. However, current levels remain as much as 100 times higher than preindustrial levels [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/6,7\">",
"     6,7",
"    </a>",
"    ] due, in part, to release from lead body stores and continued external exposure.",
"   </p>",
"   <p>",
"    In comparison to blood lead, cortical bone lead reflects cumulative lead exposure and the potential for endogenous exposure since bone lead is mobilizable into the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. Cortical bone lead is measured by x-ray fluorescence (XRF) in the mid-shaft of the tibia. The half-life is estimated to be 10 to 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/2\">",
"     2",
"    </a>",
"    ]. Body burden from past environmental exposure can be substantial. For example, the average bone lead in chronically exposed lead workers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/9\">",
"     9",
"    </a>",
"    ] was only twice that found in a study of Baltimore residents, between 50 and 70 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lead in trabecular bone (measured in the patella or calcaneus) is more bioavailable than lead in cortical bone and has a shorter half-life. As a result, it may be the best measure of lead dose that is both cumulative and bioavailable, although measurement precision is lower than cortical bone lead, which has been a limiting factor in use of this measure to date [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chelatable lead is thought to represent a bioavailable pool of lead from blood, soft tissue, and bone. Diagnostic chelation, in which lead in urine is measured following administration of a chelating agent, can estimate the size of this pool. Removal of lead from these body stores is the therapeutic principle behind the clinical use of chelation as a component of therapy in selected patients with lead poisoning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link&amp;anchor=H21#H21\">",
"     \"Adult lead poisoning\", section on 'Chelation therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link\">",
"     \"Childhood lead poisoning: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     LEAD NEPHROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lead nephropathy, which is characterized histologically by chronic interstitial nephritis, is a potential complication of prolonged (5 to 30 years), high-level lead exposure (ie, blood lead levels persistently &gt;60",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [2.9",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. At this level of exposure, lead is generally the primary cause of renal pathology.",
"   </p>",
"   <p>",
"    In addition to nephrotoxicity, lead exposure may be associated with both hypertension and increased cardiovascular risk. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link&amp;anchor=H5#H5\">",
"     \"Adult lead poisoning\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lead nephropathy is increasingly rare, particularly in developed countries, where lead exposure has been reduced through occupational and environmental controls, such as the phase-out of leaded gasoline (",
"    <a class=\"graphic graphic_figure graphicRef60319 \" href=\"UTD.htm?24/52/25422\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute, high-level lead poisoning (blood lead level &gt;100",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [4.8",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    initially injures the proximal tubules in association with intranuclear inclusion bodies composed of a lead-protein complex [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/16\">",
"     16",
"    </a>",
"    ]. With more prolonged lead exposure, renal biopsy reveals the typical changes of a chronic interstitial nephritis, including nonspecific tubular atrophy, interstitial fibrosis, a paucity of inflammatory cells and hypertrophic arteriolar changes; glomerular scarring is a secondary event [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/11,17,18\">",
"     11,17,18",
"    </a>",
"    ]. Proximal tubular intranuclear inclusion bodies are often absent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/16,18\">",
"     16,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical renal manifestations of high level lead exposure vary by time of the exposure. Signs of a Fanconi-type syndrome, such as glucosuria, aminoaciduria, and renal phosphate wasting have been observed in patients, generally children, with acute, high-level lead poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/18\">",
"     18",
"    </a>",
"    ]. These findings reflect diminished reabsorption due to proximal tubular injury and are associated with intranuclear inclusion bodies. The Fanconi syndrome generally resolves with treatment of lead poisoning, although glucosuria and aminoaciduria may persist for a prolonged period [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with lead nephropathy due to more prolonged exposure usually present with an elevated serum creatinine, little or no proteinuria, a relatively normal urine sediment, and hyperuricemia; a history of gout is frequently obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/13,15,18\">",
"     13,15,18",
"    </a>",
"    ]. These manifestations are not specific and lead nephropathy may be confused with chronic urate nephropathy, which, in the absence of tophaceous gout, is a relatively rare condition, or hypertensive nephrosclerosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link\">",
"     \"Uric acid renal diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Careful evaluation of patients considered to have chronic urate nephropathy or hypertensive nephrosclerosis in selected studies performed in the 1980s revealed that many actually had lead nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. However, the applicability of these findings to current practice is uncertain, since the high-level lead exposure required to cause lead nephropathy is increasingly rare.",
"   </p>",
"   <p>",
"    The signs and symptoms of lead poisoning in other systems may increase suspicion for lead nephropathy; these manifestations are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link\">",
"     \"Adult lead poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of lead nephropathy requires the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identification of potential current or past sources of lead exposure (",
"      <a class=\"graphic graphic_table graphicRef62969 \" href=\"UTD.htm?30/45/31453\">",
"       table 1",
"      </a>",
"      ). A patient-administered questionnaire is useful as a screening tool to identify the need to explore specific lead sources in greater detail (",
"      <a class=\"graphic graphic_figure graphicRef51152 \" href=\"UTD.htm?6/53/7007\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link&amp;anchor=H3#H3\">",
"       \"Adult lead poisoning\", section on 'Sources of exposure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11001?source=see_link&amp;anchor=H2#H2\">",
"       \"Childhood lead poisoning: Exposure and prevention\", section on 'Exposure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Assessment for the extrarenal signs and symptoms of lead poisoning.",
"     </li>",
"     <li>",
"      Lead dose assessment by measuring lead in whole blood. However, blood lead may not be elevated if high level lead exposure has declined or stopped. In the original studies describing lead nephropathy, diagnostic chelation was performed. Urinary lead excretion exceeding 600 mcg (2.9 micromol) in the 72 hours after administration of 1 gram of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/27/12726?source=see_link\">",
"       calcium EDTA",
"      </a>",
"      intravenously over one to two hours indicated a lead body burden capable of causing lead nephropathy. However, as discussed below, chelation has potential side effects and should only be performed if the results would change patient management. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link&amp;anchor=H21#H21\">",
"       \"Adult lead poisoning\", section on 'Chelation therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of lead poisoning in both adults and children is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link&amp;anchor=H14#H14\">",
"     \"Adult lead poisoning\", section on 'Diagnostic evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link&amp;anchor=H16#H16\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minimizing further exogenous lead exposure is essential in the treatment of lead nephropathy. If exposure is occupational, referral to an occupational medicine clinician with expertise in lead exposure, workplace accommodations, and workers' compensation is important. Follow-up blood lead measurements, if elevated initially, are also recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link&amp;anchor=H26#H26\">",
"     \"Adult lead poisoning\", section on 'Referral'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link&amp;anchor=H19#H19\">",
"     \"Adult lead poisoning\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link\">",
"     \"Childhood lead poisoning: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chelation therapy, based on blood lead levels and symptoms, is clearly indicated for certain patients with lead poisoning. In the absence of such indications, the data are limited concerning the renal benefits of therapeutic chelation in patients with lead nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/13,23,24\">",
"     13,23,24",
"    </a>",
"    ]. One study described the results of chelation therapy in eight lead workers with excessive body lead burdens, defined as urinary lead excretion exceeding 1000 mcg (4.8 micromol) in the 24 hours after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/27/12726?source=see_link\">",
"     calcium EDTA",
"    </a>",
"    chelation, and glomerular filtration rates less than 90",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/13\">",
"     13",
"    </a>",
"    ]. Renal biopsy confirmed the diagnosis of chronic interstitial nephritis, consistent with lead nephropathy and excluded other causes. The patients were treated with calcium EDTA three times weekly for 6 to 50 months; four had an increase in glomerular filtration rate of 20 percent or more.",
"   </p>",
"   <p>",
"    The mechanism of benefit from chelation therapy in patients with lead nephropathy is not well understood. Studies in rodent models of lead nephropathy found that the improvement in glomerular filtration rate was not associated with a similar degree of histologic improvement, particularly in regard to tubulointerstitial fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential adverse effect of chelation therapy is redistribution of lead into the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Mobilization of lead from bone and subsequent excretion via the kidneys is also a potential concern; both are greater at the higher lead body burdens present in lead nephropathy than in the chelation studies discussed below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link&amp;anchor=H21#H21\">",
"     \"Adult lead poisoning\", section on 'Chelation therapy'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H9\">",
"     'Lead-related nephrotoxicity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Acute renal failure was noted in reports from the early 1980s of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/27/12726?source=see_link\">",
"     calcium EDTA",
"    </a>",
"    therapy given at high doses and, in children, when combined with another chelator [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]. Adverse renal effects were not observed in subsequent studies in adults using lower EDTA doses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/28,31-35\">",
"     28,31-35",
"    </a>",
"    ]. However, published chelation experience in patients with renal insufficiency, particularly those with high lead body burdens, is limited.",
"   </p>",
"   <p>",
"    Thus, in the absence of elevated blood lead levels and symptoms, the decision to chelate must be made on a case-by-case basis. Referral to a clinician with experience in lead toxicity and chelation is recommended. If chelation is indicated, patients with underlying renal insufficiency should have the dose adjusted for renal function. Careful follow-up is required. Calcium disodium EDTA should be used, not disodium EDTA. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/27/12726?source=see_link\">",
"     \"Edetate calcium disodium (calcium EDTA): Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LEAD-RELATED NEPHROTOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged lead exposure at the lower levels currently encountered in developed countries may contribute to renal toxicity, which we refer to as lead-related nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/1\">",
"     1",
"    </a>",
"    ]. This is most likely to occur in patients at increased risk for kidney disease, including those with diabetes mellitus or hypertension, and in patients with underlying chronic kidney disease from non-lead causes. These patients typically do not have extrarenal manifestations of lead poisoning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Studies supporting the association of lead with nephrotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of lead-related nephrotoxicity has been evaluated in studies in the general population and in specific susceptible patient populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Risk in general population",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of participants recruited from general populations have generally observed significant associations between higher lead dose and worse renal function, particularly in patients with diabetes mellitus or hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/1,36-43\">",
"     1,36-43",
"    </a>",
"    ]. Mean blood lead levels were less than 10",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.48",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in almost all of these studies.",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings from cross-sectional studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 965 men and 1016 women (age 20 to 88 years), mean creatinine clearance was 99 and 80",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      and mean blood lead concentration was 11.4 and 7.5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (0.55 and 0.36",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      in men and women, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/36\">",
"       36",
"      </a>",
"      ]. After adjustment, a 10-fold increase in blood lead was associated with a 10 and 13",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      lower creatinine clearance in men and women, respectively.",
"     </li>",
"     <li>",
"      A report from the Third National Health and Nutrition Examination Survey (NHANES III) included over 15,000 adults in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/37\">",
"       37",
"      </a>",
"      ]. Among 4813 participants with hypertension, 10 percent had an estimated glomerular filtration rate (eGFR) less than 60",
"      <span class=\"nowrap\">",
"       mL/min/1.73",
"      </span>",
"      m2. The likelihood of having an eGFR less than 60",
"      <span class=\"nowrap\">",
"       mL/min/1.73",
"      </span>",
"      m2 was significantly higher in the highest compared with lowest quartile of blood lead (adjusted odds ratio 2.60, 95% CI 1.52-4.45). There was no such association in individuals who were normotensive.",
"     </li>",
"     <li>",
"      An analysis of NHANES 1999 to 2006 data examined associations at even lower blood lead levels. In 14,778 adults, the prevalence of chronic kidney disease (defined as an eGFR less than 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2) was approximately 50 percent higher in individuals whose blood level was greater than 2.4",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      compared with those whose level was less than or equal to 1.1",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (adjusted odds ratio 1.56, 95% CI 1.17-2.08) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A major weakness of these cross-sectional studies is the potential for reverse causality; specifically, reduced kidney function may have led to increased blood lead levels. Thus, the strongest evidence in the general population supporting a link between chronic lead exposure and nephrotoxicity is provided by prospective analyses of the Normative Aging Study [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/38\">",
"     38",
"    </a>",
"    ]. A higher long-term lead burden, assessed by tibia lead levels, was associated with a significantly greater 10 year increase in serum creatinine in individuals with diabetes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypertension (1.08 versus 0.06",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [99.5 versus 5.5",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    comparing the highest and lowest quartiles of tibia lead in diabetics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Risk in susceptible patient populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in selective patient populations have focused on chronic kidney disease (CKD), gout,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypertension since these diseases have been observed in high level lead exposure. In early studies, body lead burden assessed by diagnostic chelation was high [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/22,31\">",
"     22,31",
"    </a>",
"    ]. In a 1996 study from Spain, for example, 72-hour post-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/27/12726?source=see_link\">",
"     calcium EDTA",
"    </a>",
"    lead excretion was greater than 600 mcg (2.9 micromol) in 16 of 104 patients (15 percent) with hypertension and normal renal function and 74 of 132 patients (56 percent) with CKD of unknown etiology and hypertension, the majority of whom also had gout [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/31\">",
"     31",
"    </a>",
"    ]. In contrast, this high level of post-calcium EDTA lead excretion was not seen in any of the 30 control participants or the 30 patients with CKD of known non-lead related etiology. None of the participants in this study had a history of lead exposure.",
"   </p>",
"   <p>",
"    More recent studies included longitudinal assessment of patients at earlier stages of CKD and with much lower body lead burdens (72-hour post-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/27/12726?source=see_link\">",
"     calcium EDTA",
"    </a>",
"    lead excretion less than 600 mcg [2.9 micromol]) (",
"    <a class=\"graphic graphic_table graphicRef72174 \" href=\"UTD.htm?29/47/30460\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/32-34,45\">",
"     32-34,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The longest prospective study evaluated 121 patients with nondiabetic CKD in Taiwan who, at study entry, had a mean serum creatinine of 2.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (186",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and a mean estimated glomerular filtration rate of 36",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/45\">",
"     45",
"    </a>",
"    ]. The patients had no history of exposure to lead and had a normal body lead burden, defined as a 72-hour post-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/27/12726?source=see_link\">",
"     calcium EDTA",
"    </a>",
"    lead excretion less than 600 mcg (2.9 micromol). The 72-hour post-calcium EDTA lead excretion was between 80 and 599 mcg (0.4 and 2.9 micromol) in 63 patients (high-normal body lead burden), and below 80 mcg (0.4 micromol) in 58 (low-normal body lead burden); mean blood lead levels were 4.9 and 3.4",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.24 and 0.16",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    respectively. Renal function was similar in the two groups at baseline.",
"   </p>",
"   <p>",
"    The primary end point of doubling of the serum creatinine or the need for dialysis at four years occurred significantly more often in the patients with high-normal body lead burden (23.8 versus 3.4 percent). In addition, each 1",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.05",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    increase in blood lead level at baseline was associated with a 4.0",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 reduction in estimated glomerular filtration rate over the four-year follow-up period.",
"   </p>",
"   <p>",
"    Further evidence for the importance of low level lead exposure in patients with nondiabetic and diabetic CKD comes from randomized trials, performed by the same group in Taiwan, showing that chelation therapy slows the rate of loss of glomerular filtration rate compared to controls not treated with chelation therapy. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Chelation therapy and CKD progression'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Risk in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general manifestations of lead poisoning in children are discussed elsewhere. The renal manifestations will be reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Queensland, Australia epidemic of end-stage renal disease in children who had chronic lead poisoning and were not treated with chelation demonstrated the nephrotoxicity of chronic, high-level lead exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/11\">",
"     11",
"    </a>",
"    ]. However, studies in children and adults who had less severe childhood lead poisoning",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    were treated with chelation have not observed this degree of clinical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/19,46,47\">",
"     19,46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three general population studies of low-level lead exposure that assessed clinical renal outcomes reported inconsistent findings. A positive association between blood lead and serum cystatin C was observed in 200 Belgian adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/48\">",
"     48",
"    </a>",
"    ], while higher blood lead was associated with lower serum creatinine and cystatin C in 600 European children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among 769 adolescents aged 12 to 20 years who participated in NHANES III (1988 to 1994), higher blood lead levels were associated with lower cystatin-C based estimated GFRs; those with lead levels &gt;3.0",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    had lower estimated GFRs compared with those whose levels were &lt;1",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/50\">",
"     50",
"    </a>",
"    ]. In a model adjusted for age, sex,",
"    <span class=\"nowrap\">",
"     race/ethnicity,",
"    </span>",
"    urban versus rural residence, tobacco smoke exposure, obesity, household income and education, a twofold higher blood lead level was associated with a 2.9",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m2 lower estimated GFR. Analyses using creatinine-based equations showed similar associations between blood lead and estimated GFR, although the associations were not significant. Notably, 99 percent of the study participants had blood lead levels below 10",
"    <span class=\"nowrap\">",
"     mcg/dL.",
"    </span>",
"   </p>",
"   <p>",
"    Childhood lead poisoning is a risk for hypertension in adulthood. In a 50-year follow-up study, 21 adults with documented lead poisoning between 1930 and 1942 were compared with 21 control subjects matched for age, sex, race, and neighborhood [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/46\">",
"     46",
"    </a>",
"    ]. Although blood lead and serum creatinine levels were low in both groups, the individuals with prior lead poisoning had a marked sevenfold increase in the risk of hypertension compared to controls (relative risk 7.0, 95% CI 1.2-42.3).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Chelation studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further support for lead-induced nephrotoxicity as a risk factor for progression of underlying CKD comes from trials of chelation therapy. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Chelation therapy and CKD progression'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Lead-induced hyperfiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be an association between higher lead dose and an initial increase in glomerular filtration rate as manifested by a lower serum creatinine concentration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a higher creatinine clearance. These findings have been reported in lead workers in Korea, Belgium, and Taiwan [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/9,51,52\">",
"     9,51,52",
"    </a>",
"    ], in European children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/49\">",
"     49",
"    </a>",
"    ], and in adult survivors of childhood lead poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Korean lead workers, the associations of higher lead dose with lower serum creatinine and higher creatinine clearance were noted in younger workers, while older workers had the expected association between higher lead dose and higher serum creatinine concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/9\">",
"     9",
"    </a>",
"    ]. These findings are consistent with initial lead-induced hyperfiltration followed by later lead-induced decline in renal function. Similar findings have been noted in a rat model of lead-related nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Studies refuting the association of lead with nephrotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all studies support an association between low-level lead exposure and chronic kidney disease. In a population-based case-control study of 926 patients with severe CKD (defined as creatinine &gt;3.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    for men and &gt;2.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    for women) and 998 controls, the adjusted odds ratio was 0.97 in for those with occupational lead exposure compared with those not exposed via their occupation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/53\">",
"     53",
"    </a>",
"    ]. However, it is important to note that lead exposure was not measured but rather defined using an expert rating method based on job history. The patients with severe CKD from this study were then followed prospectively for a mean 2.5 years. The rate of progression of CKD was similar in those exposed and not exposed to lead through their occupations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/53\">",
"     53",
"    </a>",
"    ]. The severity of CKD in the population (mean MDRD estimated glomerular filtration rate &lt;20",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m2) and the small number of participants with a history of occupational lead exposure (n = 70) may have limited the ability of the study to detect a difference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Evaluation and therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the observed association between low level lead exposure and an increased rate of progression of chronic kidney disease (CKD) in selected patients, we suggest screening patients who have stage 3 or greater CKD (estimated glomerular filtration rate &lt;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) for lead exposure, using the provided questionnaire (",
"    <a class=\"graphic graphic_figure graphicRef51152 \" href=\"UTD.htm?6/53/7007\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If the screening questionnaire indicates current or substantial past (eg, occupational) exposure to lead, we recommend eliminating all sources of exposure (",
"    <a class=\"graphic graphic_table graphicRef62969 \" href=\"UTD.htm?30/45/31453\">",
"     table 1",
"    </a>",
"    ) and obtaining a whole blood lead measurement. Although blood lead does not adequately assess lead body burden, other lead dose assessment options (eg, bone lead by XRF) are not readily available or commonly used in clinical practice.",
"   </p>",
"   <p>",
"    Interpretation of the blood lead level requires an understanding of data from the general population. NHANES data from 2007 to 2008, well after the removal of lead from gasoline in the United States, revealed a geometric mean blood lead level of 1.38",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.067",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in adults age 20 and older [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Measurement of lead dose'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In developed countries, blood lead levels greater than 5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.24",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    should be rechecked approximately four weeks after the identified source of lead exposure is eliminated. In developed countries, such values are more likely to be due to exogenous exposure that can be identified and reduced.",
"   </p>",
"   <p>",
"    Patients who have repeated blood lead levels greater than 5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.24",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    should be referred to a clinician with expertise in occupational and environmental medicine. A higher blood lead referral level may be necessary in countries in which there is a greater degree of lead exposure (eg, leaded gasoline has not been banned) and occupational and environmental medicine specialists are rare.",
"   </p>",
"   <p>",
"    Occupationally exposed patients with CKD should have their lead exposure minimized to levels far below those legally mandated. Referral to an occupational medicine clinician with expertise in lead exposure and workplace accommodation may minimize adverse effects on employment and earning capacity while preserving health.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Chelation therapy and CKD progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chelation therapy in patients with lead nephropathy resulting from high level lead exposure is discussed above. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A number of clinical trials, all from the same group in Taiwan, have demonstrated efficacy from chelation therapy in patients with nondiabetic and diabetic chronic kidney disease (CKD) who had no history of exposure to lead [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. One of these trials included 64 patients with nondiabetic progressive chronic kidney disease who had baseline serum creatinine concentration between 1.5 and 3.9",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133 and 345",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    72-hour post-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/27/12726?source=see_link\">",
"     calcium EDTA",
"    </a>",
"    lead excretion of 80 to 599 mcg (0.4 to 2.9 micromol), and had been observed for 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patients were randomly assigned to placebo infusions or weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/27/12726?source=see_link\">",
"     calcium EDTA",
"    </a>",
"    chelation therapy (1 g) for three months, unless 72-hour post-calcium EDTA lead excretion fell below 60 mcg (0.29 micromol). Weekly chelation was repeated over the next two years if there were increases in serum creatinine in association with rebound increases in 72-hour post-calcium EDTA lead excretion. Baseline mean blood lead levels were approximately 6.0",
"    <span class=\"nowrap\">",
"     &micro;g/dL",
"    </span>",
"    (0.29",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in the treated and control groups. At 27 months, chelation therapy was associated with a slowing or reversal of the progressive decline in glomerular filtration rate compared with placebo (mean change of +2.1 versus -6.0",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2).",
"   </p>",
"   <p>",
"    A later randomized trial by the same group demonstrated a similar magnitude of benefit from chelation therapy in CKD patients with the lowest body lead burden studied to date (defined as 72-hour post-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/27/12726?source=see_link\">",
"     calcium EDTA",
"    </a>",
"    lead excretion between 20 and 79 mcg [0.10 and 0.38 micromol]) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/34\">",
"     34",
"    </a>",
"    ]. The baseline mean blood lead level in the treated group in this study was 2.6",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.13",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"   </p>",
"   <p>",
"    In summary, the demonstration of benefit from chelation therapy in CKD patients with low level lead exposure raises two mechanistic possibilities, both of which may be involved:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lead-related nephrotoxicity contributes to progression in CKD patients, a hypothesis supported by longitudinal observational data on lead as a risk factor for progression in CKD patients.",
"     </li>",
"     <li>",
"      The benefits of chelation therapy may be due to mechanisms other than removal of body lead stores. Consistent with this hypothesis is the observation that chelation therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/26/12709?source=see_link\">",
"       dimercaptosuccinic acid",
"      </a>",
"      (DMSA) had a beneficial effect on nephrosclerosis in a non-lead exposed rat model [",
"      <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, important questions remain regarding the benefits of chelation in selected patients with CKD. As discussed above, there are potential concerns about the safety of chelation related to both redistribution of lead into the central nervous system and toxicity of the chelating agents. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Treatment'",
"    </a>",
"    above.) Of particular relevance for the low lead setting, cognitive impairment has been reported in non-lead exposed control rats following chelation with succimer [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, all of the above studies were performed at one medical center in small groups of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/36/5705/abstract/32-35\">",
"     32-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Confirmation of the efficacy and safety of chelation therapy in CKD patients with low level lead exposure is required in larger, racially diverse populations at additional centers. Given the size of the potentially affected population, this approach could yield important public health benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High levels of chronic lead exposure can cause lead nephropathy. In addition, lower levels of chronic lead exposure may contribute to lead-related nephrotoxicity in patients who already have or are at increased risk for chronic kidney disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Lead-related nephrotoxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lead may be measured in whole blood, bone, and, following administration of a chelating agent, urine. Blood lead is used most commonly in the clinical setting, while bone lead is primarily a research tool. Diagnostic chelation is sometimes used to assess bioavailable lead body burden. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Measurement of lead dose'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link&amp;anchor=H21#H21\">",
"       \"Adult lead poisoning\", section on 'Chelation therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link\">",
"       \"Childhood lead poisoning: Management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lead nephropathy is characterized by chronic interstitial nephritis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of acute lead poisoning include the Fanconi syndrome. After more prolonged high-level exposure, patients present with an elevated serum creatinine, little or no proteinuria, and a relatively normal urine sediment. Hyperuricemia, gout, and hypertension may also be present. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prolonged lead exposure at the lower levels currently encountered in developed countries may contribute to renal toxicity. This is referred to as lead-related nephrotoxicity. These patients typically do NOT have extrarenal manifestations of lead poisoning. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Lead-related nephrotoxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the possibility of lead-related nephrotoxicity in those with chronic kidney disease (CKD), we suggest screening patients who have stage 3 or greater CKD (estimated glomerular filtration rate &lt;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2) for lead exposure using a self-administered questionnaire (",
"      <a class=\"graphic graphic_figure graphicRef51152 \" href=\"UTD.htm?6/53/7007\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Evaluation and therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the screening questionnaire indicates current exposure to lead, all sources of exposure should be eliminated (",
"      <a class=\"graphic graphic_table graphicRef62969 \" href=\"UTD.htm?30/45/31453\">",
"       table 1",
"      </a>",
"      ), and a blood lead level measured. If the blood lead level is greater than 5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (0.24",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      levels should be rechecked four weeks after the identified source of lead exposure is eliminated. We recommend referral to a clinician with expertise in occupational and environmental medicine if the blood lead is persistently greater than 5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (0.24",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Evaluation and therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Minimizing further lead exposure is essential in the treatment of lead nephropathy. Chelation therapy is indicated for select patients with nephropathy in the setting of acute lead poisoning, based on elevated blood lead levels and lead-related symptoms. In the absence of such indications, the decision to chelate must be made on an individualized basis, and referral to a clinician with experience in lead toxicity and chelation is recommended. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link&amp;anchor=H19#H19\">",
"       \"Adult lead poisoning\", section on 'Management'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link\">",
"       \"Childhood lead poisoning: Management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Confirmation of the efficacy and safety of chelation therapy in CKD patients with low level lead exposure is required in larger, racially diverse populations in additional research centers before such therapy can be recommended. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Chelation therapy and CKD progression'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/1\">",
"      Ekong EB, Jaar BG, Weaver VM. Lead-related nephrotoxicity: a review of the epidemiologic evidence. Kidney Int 2006; 70:2074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/2\">",
"      Hu H, Rabinowitz M, Smith D. Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms. Environ Health Perspect 1998; 106:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/3\">",
"      Hu H, Payton M, Korrick S, et al. Determinants of bone and blood lead levels among community-exposed middle-aged to elderly men. The normative aging study. Am J Epidemiol 1996; 144:749.",
"     </a>",
"    </li>",
"    <li>",
"     National Center for Health Statistics, Annest, JL, Mahaffey, K. Blood lead levels for persons ages 6 months-74 years, United States, 1976-80. Vital and Health Statistics. Series 11, No. 233. DHHS Pub. No. (PHS) 84-1683. Public Health Service. Washington. U.S. Government Printing Office, August 1984.",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Fourth National Report on Human Exposure to Environmental Chemicals, Updated Tables. Department of Health and Human Services, Atlanta, Georgia. February 2012 pp 136.",
"    </li>",
"    <li>",
"     U.S. Environmental Protection Agency. Air Quality Criteria for Lead (Final) Volume I,. Washington, DC, EPA/600/R-05/144aF-bF, 2006. p. 6. Available: file://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=158823.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/7\">",
"      Flegal AR, Smith DR. Lead levels in preindustrial humans. N Engl J Med 1992; 326:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/8\">",
"      Barbosa F Jr, Tanus-Santos JE, Gerlach RF, Parsons PJ. A critical review of biomarkers used for monitoring human exposure to lead: advantages, limitations, and future needs. Environ Health Perspect 2005; 113:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/9\">",
"      Weaver VM, Lee BK, Ahn KD, et al. Associations of lead biomarkers with renal function in Korean lead workers. Occup Environ Med 2003; 60:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/10\">",
"      Martin D, Glass TA, Bandeen-Roche K, et al. Association of blood lead and tibia lead with blood pressure and hypertension in a community sample of older adults. Am J Epidemiol 2006; 163:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/11\">",
"      Inglis JA, Henderson DA, Emmerson BT. The pathology and pathogenesis of chronic lead nephropathy occurring in Queensland. J Pathol 1978; 124:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/12\">",
"      Steenland K, Selevan S, Landrigan P. The mortality of lead smelter workers: an update. Am J Public Health 1992; 82:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/13\">",
"      Wedeen RP, Malik DK, Batuman V. Detection and treatment of occupational lead nephropathy. Arch Intern Med 1979; 139:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/14\">",
"      Khalil-Manesh F, Gonick HC, Cohen AH, et al. Experimental model of lead nephropathy. I. Continuous high-dose lead administration. Kidney Int 1992; 41:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/15\">",
"      Bennett WM. Lead nephropathy. Kidney Int 1985; 28:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/16\">",
"      Goyer RA, Rhyne BC. Pathological effects of lead. Int Rev Exp Pathol 1973; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/17\">",
"      Wedeen RP, Maesaka JK, Weiner B, et al. Occupational lead nephropathy. Am J Med 1975; 59:630.",
"     </a>",
"    </li>",
"    <li>",
"     Wedeen, RP, Emmerson, BT. Lead nephropathy. In: Clinical Nephrotoxins, De Broe, ME, Porter, GA, Bennett, WM, Verpooten GA (Eds), Kluwer Academic Publishers, The Netherlands, 2003, p. 495.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/19\">",
"      Loghman-Adham M. Aminoaciduria and glycosuria following severe childhood lead poisoning. Pediatr Nephrol 1998; 12:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/20\">",
"      Batuman V, Maesaka JK, Haddad B, et al. The role of lead in gout nephropathy. N Engl J Med 1981; 304:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/21\">",
"      Craswell PW, Price J, Boyle PD, et al. Chronic renal failure with gout: a marker of chronic lead poisoning. Kidney Int 1984; 26:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/22\">",
"      Batuman V, Landy E, Maesaka JK, Wedeen RP. Contribution of lead to hypertension with renal impairment. N Engl J Med 1983; 309:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/23\">",
"      Morgan JM. Chelation therapy in lead nephropathy. South Med J 1975; 68:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/24\">",
"      Germain MJ, Braden GL, Fitzgibbons JP. Failure of chelation therapy in lead nephropathy. Arch Intern Med 1984; 144:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/25\">",
"      Khalil-Manesh F, Gonick HC, Cohen A, et al. Experimental model of lead nephropathy. II. Effect of removal from lead exposure and chelation treatment with dimercaptosuccinic acid (DMSA). Environ Res 1992; 58:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/26\">",
"      S&aacute;nchez-Fructuoso AI, Blanco J, Cano M, et al. Experimental lead nephropathy: treatment with calcium disodium ethylenediaminetetraacetate. Am J Kidney Dis 2002; 40:59.",
"     </a>",
"    </li>",
"    <li>",
"     Fischbein, A, Hu, H. Occupational and environmental exposure to lead. In: Environmental and Occupational Medicine, Rom, WN and Markowitz, SB (Eds), Philadelphia, Wolters Kluwer/Lippincott Williams &amp; Wilkins 2007. p. 954.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/28\">",
"      Wedeen RP, Batuman V, Landy E. The safety of the EDTA lead-mobilization test. Environ Res 1983; 30:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/29\">",
"      Stangle DE, Smith DR, Beaudin SA, et al. Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure. Environ Health Perspect 2007; 115:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/30\">",
"      Moel DI, Kumar K. Reversible nephrotoxic reactions to a combined 2,3-dimercapto-1-propanol and calcium disodium ethylenediaminetetraacetic acid regimen in asymptomatic children with elevated blood lead levels. Pediatrics 1982; 70:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/31\">",
"      S&aacute;nchez-Fructuoso AI, Torralbo A, Arroyo M, et al. Occult lead intoxication as a cause of hypertension and renal failure. Nephrol Dial Transplant 1996; 11:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/32\">",
"      Lin JL, Lin-Tan DT, Hsu KH, Yu CC. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med 2003; 348:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/33\">",
"      Lin JL, Lin-Tan DT, Yu CC, et al. Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes. Kidney Int 2006; 69:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/34\">",
"      Lin JL, Lin-Tan DT, Li YJ, et al. Low-level environmental exposure to lead and progressive chronic kidney diseases. Am J Med 2006; 119:707.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/35\">",
"      Lin-Tan DT, Lin JL, Yen TH, et al. Long-term outcome of repeated lead chelation therapy in progressive non-diabetic chronic kidney diseases. Nephrol Dial Transplant 2007; 22:2924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/36\">",
"      Staessen JA, Lauwerys RR, Buchet JP, et al. Impairment of renal function with increasing blood lead concentrations in the general population. The Cadmibel Study Group. N Engl J Med 1992; 327:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/37\">",
"      Muntner P, He J, Vupputuri S, et al. Blood lead and chronic kidney disease in the general United States population: results from NHANES III. Kidney Int 2003; 63:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/38\">",
"      Tsaih SW, Korrick S, Schwartz J, et al. Lead, diabetes, hypertension, and renal function: the normative aging study. Environ Health Perspect 2004; 112:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/39\">",
"      Payton M, Hu H, Sparrow D, Weiss ST. Low-level lead exposure and renal function in the Normative Aging Study. Am J Epidemiol 1994; 140:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/40\">",
"      Akesson A, Lundh T, Vahter M, et al. Tubular and glomerular kidney effects in Swedish women with low environmental cadmium exposure. Environ Health Perspect 2005; 113:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/41\">",
"      Kim R, Rotnitsky A, Sparrow D, et al. A longitudinal study of low-level lead exposure and impairment of renal function. The Normative Aging Study. JAMA 1996; 275:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/42\">",
"      Muntner P, Menke A, DeSalvo KB, et al. Continued decline in blood lead levels among adults in the United States: the National Health and Nutrition Examination Surveys. Arch Intern Med 2005; 165:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/43\">",
"      Spector JT, Navas-Acien A, Fadrowski J, et al. Associations of blood lead with estimated glomerular filtration rate using MDRD, CKD-EPI and serum cystatin C-based equations. Nephrol Dial Transplant 2011; 26:2786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/44\">",
"      Navas-Acien A, Tellez-Plaza M, Guallar E, et al. Blood cadmium and lead and chronic kidney disease in US adults: a joint analysis. Am J Epidemiol 2009; 170:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/45\">",
"      Yu CC, Lin JL, Lin-Tan DT. Environmental exposure to lead and progression of chronic renal diseases: a four-year prospective longitudinal study. J Am Soc Nephrol 2004; 15:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/46\">",
"      Hu H. A 50-year follow-up of childhood plumbism. Hypertension, renal function, and hemoglobin levels among survivors. Am J Dis Child 1991; 145:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/47\">",
"      Moel DI, Sachs HK. Renal function 17 to 23 years after chelation therapy for childhood plumbism. Kidney Int 1992; 42:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/48\">",
"      Staessen JA, Nawrot T, Hond ED, et al. Renal function, cytogenetic measurements, and sexual development in adolescents in relation to environmental pollutants: a feasibility study of biomarkers. Lancet 2001; 357:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/49\">",
"      de Burbure C, Buchet JP, Leroyer A, et al. Renal and neurologic effects of cadmium, lead, mercury, and arsenic in children: evidence of early effects and multiple interactions at environmental exposure levels. Environ Health Perspect 2006; 114:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/50\">",
"      Fadrowski JJ, Navas-Acien A, Tellez-Plaza M, et al. Blood lead level and kidney function in US adolescents: The Third National Health and Nutrition Examination Survey. Arch Intern Med 2010; 170:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/51\">",
"      Roels H, Lauwerys R, Konings J, et al. Renal function and hyperfiltration capacity in lead smelter workers with high bone lead. Occup Environ Med 1994; 51:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/52\">",
"      Hsiao CY, Wu HD, Lai JS, Kuo HW. A longitudinal study of the effects of long-term exposure to lead among lead battery factory workers in Taiwan (1989-1999). Sci Total Environ 2001; 279:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/53\">",
"      Evans M, Fored CM, Nise G, et al. Occupational lead exposure and severe CKD: a population-based case-control and prospective observational cohort study in Sweden. Am J Kidney Dis 2010; 55:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/36/5705/abstract/54\">",
"      Gonick HC, Cohen AH, Ren Q, et al. Effect of 2,3-dimercaptosuccinic acid on nephrosclerosis in the Dahl rat. I. Role of reactive oxygen species. Kidney Int 1996; 50:1572.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7180 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-210.101.131.232-8FC26C7E2B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_36_5705=[""].join("\n");
var outline_f5_36_5705=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SOURCES OF LEAD EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MEASUREMENT OF LEAD DOSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LEAD NEPHROPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LEAD-RELATED NEPHROTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Studies supporting the association of lead with nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Risk in general population",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Risk in susceptible patient populations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Risk in children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Chelation studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Lead-induced hyperfiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Studies refuting the association of lead with nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Evaluation and therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Chelation therapy and CKD progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7180\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7180|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/52/25422\" title=\"figure 1\">",
"      Leaded gasoline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/53/7007\" title=\"figure 2\">",
"      Lead exposure questionnaire",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7180|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/45/31453\" title=\"table 1\">",
"      Lead exposure sources list",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/47/30460\" title=\"table 2\">",
"      Lead and CKD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=related_link\">",
"      Adult lead poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=related_link\">",
"      Childhood lead poisoning: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11001?source=related_link\">",
"      Childhood lead poisoning: Exposure and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=related_link\">",
"      Childhood lead poisoning: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/27/12726?source=related_link\">",
"      Edetate calcium disodium (calcium EDTA): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=related_link\">",
"      Uric acid renal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_36_5706="Carbamazepine: Pediatric drug information";
var content_f5_36_5706=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carbamazepine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"    see \"Carbamazepine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/8/13446?source=see_link\">",
"    see \"Carbamazepine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F145588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carbatrol&reg;;",
"     </li>",
"     <li>",
"      Epitol&reg;;",
"     </li>",
"     <li>",
"      Equetro&reg;;",
"     </li>",
"     <li>",
"      TEGretol&reg;;",
"     </li>",
"     <li>",
"      TEGretol&reg;-XR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F145589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Carbamazepine&reg;;",
"     </li>",
"     <li>",
"      Dom-Carbamazepine;",
"     </li>",
"     <li>",
"      Mapezine&reg;;",
"     </li>",
"     <li>",
"      Mylan-Carbamazepine CR;",
"     </li>",
"     <li>",
"      Nu-Carbamazepine;",
"     </li>",
"     <li>",
"      PMS-Carbamazepine;",
"     </li>",
"     <li>",
"      Sandoz-Carbamazepine;",
"     </li>",
"     <li>",
"      Taro-Carbamazepine Chewable;",
"     </li>",
"     <li>",
"      Tegretol&reg;;",
"     </li>",
"     <li>",
"      Teva-Carbamazepine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"      see \"Carbamazepine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage must be adjusted according to patient's response and serum concentrations. Administer tablets (chewable or conventional) in 2-3 divided doses daily and suspension in 4 divided doses daily. Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Epilepsy:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;6 years: Initial: 10-20 mg/kg/day divided twice or 3 times daily as tablets or 4 times/day as suspension; increase dose every week until optimal response and therapeutic levels are achieved; maintenance dose: Divide into 3-4 doses daily (tablets or suspension); maximum recommended dose: 35 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-12 years: Initial: 100 mg twice daily (tablets or extended release tablets) or 50 mg of suspension 4 times/day (200 mg/day); increase by up to 100 mg/day at weekly intervals using a twice daily regimen of extended release tablets or 3-4 times daily regimen of other formulations until optimal response and therapeutic levels are achieved; usual maintenance: 400-800 mg/day; maximum recommended dose: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Children &lt;12 years who receive &ge;400 mg/day of carbamazepine may be converted to extended release capsules (Carbatrol&reg;) using the same total daily dosage divided twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12 years and Adults: Initial: 200 mg twice daily (tablets, extended release tablets, or extended release capsules) or 100 mg of suspension 4 times/day (400 mg daily); increase by up to 200 mg/day at weekly intervals using a twice daily regimen of extended release tablets or capsules, or a 3-4 times/day regimen of other formulations until optimal response and therapeutic levels are achieved; usual dose: 800-1200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maximum recommended doses:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 12-15 years: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &gt;15 years: 1200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adults: 1600 mg/day; however, some patients have required up to 1.6-2.4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bipolar disorder",
"     </b>",
"     (Equetro&trade;): Adults: Initial: 200 mg twice daily; adjust dose by 200 mg/day increments until optimal response is achieved; maximum dose: 1600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 75% of recommended dose; monitor serum levels",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F145559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral: 100 mg, 200 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carbatrol&reg;: 100 mg, 200 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Equetro&reg;: 100 mg, 200 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 100 mg/5 mL (5 mL, 10 mL, 450 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TEGretol&reg;: 100 mg/5 mL (450 mL) [contains propylene glycol; citrus-vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epitol&reg;: 200 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TEGretol&reg;: 200 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TEGretol&reg;: 100 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 200 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TEGretol&reg;-XR: 100 mg, 200 mg, 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F145544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10968527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Carbatrol&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM241639.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM241639.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Equetro&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM328348.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM328348.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     TEGretol&reg;, TEGretol&reg;-XR:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM246796.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM246796.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with food to decrease GI upset; avoid administration with grapefruit juice; extended release capsules (Carbatrol&reg;, Equetro&trade;) may be taken without regard to meals; suspension dosage should be administered on a 3-4 times/day schedule vs tablet (conventional or chewable) which can be administered 2-4 times/day; extended release (XR) tablets should be dosed twice daily; do not crush or chew XR tablets; examine XR tablets for cracks or chips; do not use damaged XR tablets or XR tablets without a release portal; chewable tablet should be chewed well and swallowed. Swallow extended release capsules whole or open and sprinkle contents on small amount of soft food (eg, 1 teaspoonful of applesauce); swallow sprinkle/food mixture immediately; do not chew; do not store for later use; drink fluids after dose to make sure mixture is completely swallowed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension: Tegretol&reg; should not be administered with diluents or other liquid medicines due to the possibility of a component interaction; shake suspension well before use",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1051484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature, below 30&deg;C (86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablets, chewable: Protect from moisture and light; dispense in tight, light-resistant container",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablets and extended release tablets: Protect from moisture; dispense in tightly closed container",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension: Dispense in tight, light-resistant container",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsules, extended release: Protect from light and moisture",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of generalized tonic-clonic, partial (especially complex partial), and mixed partial or generalized seizure disorder; to relieve pain in trigeminal neuralgia or diabetic neuropathy; treatment of bipolar disorders (Equetro&trade; is approved for this use)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F145644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       CarBAMazepine may be confused with OXcarbazepine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Epitol&reg; may be confused with Epinal&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       TEGretol&reg;, TEGretol&reg;-XR may be confused with Mebaral&reg;, Toprol-XL&reg;, Toradol&reg;, TRENtal&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F145642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, AV block, chills, coronary artery disease exacerbation, edema, heart failure, hyper-/hypotension, syncope, thromboembolism, thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal thinking, agitation, amnesia, ataxia, confusion, coordination impaired, depression, dizziness, drowsiness, fatigue, fever, hallucinations, headache, neuroleptic malignant syndrome (NMS), slurred speech, somnolence, speech disorder, talkativeness, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, alterations in skin pigmentation, erythema (multiforme and nodosum), exfoliative dermatitis, disseminated lupus erythematosus exacerbation, nail shedding, onychomadesis, photosensitivity reaction, pruritus, purpura, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypocalcemia, hyponatremia, syndrome of inappropriate ADH secretion (SIADH), thyroid function tests abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dry throat, gastric distress, glossitis, nausea, pancreatitis, stomatitis, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, urinary frequency, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia, aplastic anemia, bone marrow suppression, eosinophilia, leukocytosis, leukopenia, pancytopenia, porphyria, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Abnormal liver function tests, hepatic failure, hepatitis, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, leg cramps, myalgia, osteoporosis, paresthesia, peripheral neuritis, tremor, twitching, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, conjunctivitis, diplopia, intraocular pressure increased, lens opacities, nystagmus, oculomotor disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hyperacusis, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Albuminuria, azotemia, blood urea nitrogen increased, glycosuria, oliguria, renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, drug rash with eosinophilia and systemic symptoms (DRESS), hypersensitivity, lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Aseptic meningitis, fertility impaired (male), hirsutism, lupus erythematosus-like syndrome, paralysis, spermatogenesis abnormal, suicidal ideation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to carbamazepine, tricyclic antidepressants, or any component; patients with a history of bone marrow suppression; concomitant use or use within 14 days of MAO inhibitors; concurrent use with nefazodone",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and only after benefit-to-risk assessment in patients with history of cardiac disease, hepatic disease, renal failure, adverse hematologic reactions to other drugs, or history of hypersensitivity reactions to other anticonvulsants (eg, phenobarbital, phenytoin). Use with caution in patients with increased IOP (carbamazepine has mild anticholinergic effects). Use with caution when treating patients with a mixed seizure disorder that includes atypical absence seizures (carbamazepine may increase frequency of generalized convulsions in these patients). Higher peak concentrations occur with the suspension, so treatment is initiated with lower amounts per dose and increased slowly to avoid adverse effects.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Long-term risks and benefits of carbamazepine in the treatment of bipolar disorder have not been evaluated; periodic assessment of risks and benefits should be conducted for individual patient. For bipolar disorder, use the smallest effective dose to reduce the risk of overdose/suicide; high-risk patients should be monitored for suicidal ideations; to reduce risk of intentional overdose, write prescriptions for the smallest quantity consistent with good patient care.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1051478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Potentially fatal blood cell abnormalities (aplastic anemia and agranulocytosis) have been reported in association with carbamazepine treatment",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; history of adverse hematologic reaction to any drug may place patient at increased risk; early detection of hematologic change is important; baseline and periodic hematologic testing is recommended; advise patients of early signs and symptoms which are fever, sore throat, mouth ulcers, infections, easy bruising, petechial or purpuric hemorrhage; discontinue carbamazepine if evidence of significant bone marrow depression occurs. Potentially fatal, severe dermatologic reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis) may occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; over 90% of patients who experience these reactions do so within the first few months of treatment; patients of Asian descent are at higher risk for toxic dermatologic reactions and should be screened for the  variant",
"     <b>",
"      <i>",
"       HLA-B*1502",
"      </i>",
"     </b>",
"     allele (genetic marker) prior to initiating therapy; this genetic variant has been associated with a significantly increased risk of developing toxic dermatologic reactions; patients with a positive result should not be started on carbamazepine, unless the benefit exceeds the risks; toxic dermatologic reactions can still occur infrequently in patients of any ethnicity who test negative for",
"     <b>",
"      <i>",
"       HLA-B*1502",
"      </i>",
"     </b>",
"     . Hepatic failure (rare) and multi-organ hypersensitivity reactions may occur; consider discontinuation of carbamazepine if any evidence of hypersensitivity occurs. Do not abruptly discontinue in patients being treated for seizures (precipitation of status epilepticus may occur). Carbamazepine may activate latent psychosis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Avoid the use of carbamazepine in patients with hepatic porphyria (eg, variegate porphyria, acute intermittent porphyria, porphyria cutanea tarda); acute attacks of porphyria may occur. Substitution of Tegretol&reg; with generic carbamazepine has resulted in decreased carbamazepine levels and increased seizure activity, as well as increased carbamazepine levels and toxicity. Monitoring of carbamazepine serum concentrations is mandatory when patients are switched from any product to another.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Antiepileptic drugs (AEDs) increase the risk of suicidal behavior and ideation in patients receiving these medications for any indication. Pooled analyses of placebo-controlled trials involving 11 different AEDs (regardless of indication) showed a twofold increased risk of suicidal thoughts or behavior (estimated incidence rate: 0.43% in AED treated patients compared to 0.24% of patients receiving placebo); increased risk was observed as early as 1 week after initiation of AED and continued through duration of trials (most trials &le;24 weeks); risk did not vary significantly by age (age range: 5-100 years). Consider risks and benefits of AEDs before prescribing. Monitor all patients receiving an AED for emergence of suicidal thoughts or behavior, thoughts of self-harm, any unusual changes in behavior or mood, or the emergence or worsening of depressive symptoms; notify healthcare provider immediately if symptoms or concerning behavior occur.",
"     <b>",
"      Note:",
"     </b>",
"     The FDA is requiring that a Medication Guide be developed for all antiepileptic drugs informing patients of this risk.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F145630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C8 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP1A2 (strong), CYP2B6 (strong), CYP2C19 (strong), CYP2C8 (strong), CYP2C9 (strong), CYP3A4 (strong), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F145553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: CarBAMazepine may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenosine: CarBAMazepine may enhance the adverse/toxic effect of Adenosine. Specifically, the risk of higher degree heart block may be increased.  Management: Consider using a lower initial dose of adenosine in patients who are receiving carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May increase the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inducers (Strong) may decrease the serum concentration of Bendamustine. Concentrations of active metabolites may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): CarBAMazepine may increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: CarBAMazepine may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): CarBAMazepine may increase the metabolism of Calcium Channel Blockers (Dihydropyridine).  Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): CarBAMazepine may decrease the serum concentration of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of CarBAMazepine.  Management: Consider empiric reductions in carbamazepine dose with initiation of nondihydropyridine calcium channel blockers. Monitor for increased toxic effects of carbamazepine and reduced therapeutic effects of the calcium channel blocker.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May increase the serum concentration of CarBAMazepine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caspofungin: Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.  Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of CarBAMazepine. The serum carbamazepine concentration might return to normal within one week of starting cimetidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ClomiPRAMINE: CarBAMazepine may increase the serum concentration of ClomiPRAMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: CarBAMazepine may enhance the myelosuppressive effect of CloZAPine. CarBAMazepine may decrease the serum concentration of CloZAPine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: CarBAMazepine may decrease the serum concentration of Cobicistat.  Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): CarBAMazepine may diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): CarBAMazepine may diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): CarBAMazepine may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inducers (Strong) may increase the metabolism of CYP1A2 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inducers (Strong) may increase the metabolism of CYP2B6 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inducers (Strong) may increase the metabolism of CYP2C19 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inducers (Strong) may increase the metabolism of CYP2C8 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inducers (Strong) may increase the metabolism of CYP2C9 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: CarBAMazepine may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inducers (Strong) may decrease the serum concentration of Diclofenac (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: CarBAMazepine may increase the metabolism of Divalproex. Divalproex may decrease the serum concentration of CarBAMazepine. Carbamazepine-Epoxide concentrations might increase, offsetting the decreases in the parent compound.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxycycline: CarBAMazepine may decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: CarBAMazepine may decrease the serum concentration of Elvitegravir.  Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP2C8 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: CarBAMazepine may decrease the serum concentration of Felbamate. Felbamate may decrease the serum concentration of CarBAMazepine.  Management: In patients receiving carbamazepine, initiate felbamate at 1200 mg/day in divided doses 3-4 times daily while reducing carbamazepine dose by 20%.  Monitor for reduced concentrations/effects of both drugs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flunarizine: CarBAMazepine may decrease the serum concentration of Flunarizine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: CarBAMazepine may decrease the serum concentration of Fosphenytoin. CarBAMazepine may increase the serum concentration of Fosphenytoin. Possibly by competitive inhibition at sites of metabolism. Fosphenytoin may decrease the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: CarBAMazepine may increase the metabolism of Haloperidol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irinotecan: CarBAMazepine may decrease the serum concentration of Irinotecan. Concentrations of the active metabolite SN-38 may also be reduced.  Management: Change to a non-enzyme inducing anticonvulsant, when clinically possible, at least 2 weeks prior to beginning irinotecan.  Dosage increases for irinotecan may be needed when used with carbamazepine, but specific dosing guidelines are not available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lacosamide: CarBAMazepine may decrease the serum concentration of Lacosamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May enhance the adverse/toxic effect of CarBAMazepine. CarBAMazepine may increase the metabolism of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: CarBAMazepine may enhance the adverse/toxic effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: CarBAMazepine may decrease the serum concentration of Lopinavir.  Management: Increased doses of lopinavir may be necessary when using these agents in combination.  Do not use a once daily lopinavir/ritonavir regimen together with carbamazepine. Increase monitoring of therapeutic response in all patients using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of CarBAMazepine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: CarBAMazepine may enhance the adverse/toxic effect of MAO Inhibitors.  Management: Avoid concurrent use of carbamazepine during, or within 14 days of discontinuing, treatment with a monoamine oxidase inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mebendazole: CarBAMazepine may decrease the serum concentration of Mebendazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: CarBAMazepine may increase the metabolism of Methadone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylfolate: May decrease the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CarBAMazepine may decrease the serum concentration of MethylPREDNISolone.  Management: Consider an alternative corticosteroid. If this combination cannot be avoided, monitor for diminished methylprednisolone effects during carbamazepine treatment, and increased methylprednisolone effects following carbamazepine discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: CarBAMazepine may decrease the serum concentration of Nefazodone. Concentrations of active Nefazodone metabolites may also be reduced. Nefazodone may increase the serum concentration of CarBAMazepine. Also, concentrations of the active CarBAMazepine epoxide metabolite may be reduced.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: CarBAMazepine may decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced.  Management: Consider increasing the initial adult oxcarbazepine extended release tablet (Oxtellar XR) dose to 900 mg/day. No specific recommendations are available for other oxcarbazepine formulations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paliperidone: CarBAMazepine may decrease the serum concentration of Paliperidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CarBAMazepine may decrease the serum concentration of Perampanel.  Management: Increase the perampanel starting dose to 4 mg/day when perampanel is used with carbamazepine.  Patients receiving this combination should be followed closely for response, especially with any changes to carbamazepine therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: CarBAMazepine may decrease the serum concentration of Phenytoin. CarBAMazepine may increase the serum concentration of Phenytoin. Possibly by competitive inhibition at sites of metabolism. Phenytoin may decrease the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inducers (Strong) may decrease the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP1A2 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: CarBAMazepine may increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: CarBAMazepine may decrease the serum concentration of QuiNINE. QuiNINE may increase the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reverse Transcriptase Inhibitors (Non-Nucleoside): CarBAMazepine may decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RisperiDONE: CarBAMazepine may decrease the serum concentration of RisperiDONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: CarBAMazepine may decrease the serum concentration of Rufinamide. Rufinamide may decrease the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CarBAMazepine may increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: CarBAMazepine may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: CarBAMazepine may decrease the serum concentration of Temsirolimus. Concentrations of the active metabolite, sirolimus, are also likely to be decreased (and maybe to an even greater degree).  Management: Temsirolimus prescribing information recommends against coadministration with strong CYP3A4 inducers such as carbamazepine; however, if concurrent therapy is necessary, an increase in temsirolimus adult dose to 50 mg/week should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May decrease the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: CarBAMazepine may decrease the serum concentration of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: CarBAMazepine may decrease the serum concentration of Topiramate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: May enhance the CNS depressant effect of CarBAMazepine. TraMADol may diminish the therapeutic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of TraMADol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: CYP2C8 Inducers (Strong) may decrease the serum concentration of Treprostinil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: CarBAMazepine may increase the metabolism of Tricyclic Antidepressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     ClomiPRAMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: CarBAMazepine may increase the metabolism of Valproic Acid. Valproic Acid may decrease the serum concentration of CarBAMazepine. Carbamazepine-Epoxide concentrations might increase, offsetting the decreases in the parent compound.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vecuronium: CarBAMazepine may decrease the serum concentration of Vecuronium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): CarBAMazepine may decrease the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: CarBAMazepine may decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ziprasidone: CarBAMazepine may decrease the serum concentration of Ziprasidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: May enhance the CNS depressant effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Zolpidem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1051499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Extended release capsules (Carbatrol&reg;, Equetro&trade;): A high fat meal may increase the rate of absorption, reduce time to peak concentration (from 24 hours to 14 hours), and increase peak concentrations, but does not effect extent of absorption (AUC)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Grapefruit juice increases the oral bioavailability of carbamazepine by an average of 40%",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F145555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F145571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Studies in pregnant women have demonstrated a risk to the fetus. Carbamazepine and its metabolites can be found in the fetus and may be associated with teratogenic effects, including spina bifida, craniofacial defects, cardiovascular malformations, and hypospadias. The risk of teratogenic effects is higher with anticonvulsant polytherapy than monotherapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Developmental delays have also been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to carbamazepine (per manufacturer); however, socioeconomic factors, maternal and paternal IQ, and polytherapy may contribute to these findings. Pregnancy may cause small decreases of carbamazepine plasma concentrations in the second and third trimesters; monitoring should be considered. When used for the treatment of bipolar disorder, use of carbamazepine should be avoided during the first trimester of pregnancy if possible. The use of a single medication for the treatment of bipolar disorder or epilepsy in pregnancy is preferred. Carbamazepine may decrease plasma concentrations of hormonal contraceptives; breakthrough bleeding or unintended pregnancy may occur and alternate or back-up methods of contraception should be considered.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to carbamazepine during pregnancy are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      <i>",
"       HLA-B*1502",
"      </i>",
"     </b>",
"     genotype screening prior to therapy initiation in patients of Asian descent; CBC with platelet count, reticulocytes, serum iron, liver function tests, ophthalmic examinations (including slit-lamp, fundoscopy, and tonometry), urinalysis, BUN, lipid panel, serum drug concentrations, thyroid function tests, serum sodium; pregnancy test; observe patient for excessive sedation especially when instituting or increasing therapy; signs of edema, skin rash, and hypersensitivity reactions; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes).",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1051491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: 4-12 mcg/mL (SI: 17-51 micromoles/L). Patients who require higher levels [8-12 mcg/mL (SI: 34-51 micromoles/L)] should be carefully monitored. Side effects (especially CNS) occur commonly at higher levels. If other anticonvulsants (enzyme inducers) are given, therapeutic range is 4-8 mcg/mL (SI: 17-34 micromoles/L) due to increase in unmeasured active epoxide metabolite.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Epilepsy: May depress activity in the nucleus ventralis of the thalamus or decrease synaptic transmission or decrease summation of temporal stimulation leading to neural discharge, by limiting influx of sodium ions across cell membrane; other unknown mechanisms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bipolar disorder: Mechanism of action is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Carbamazepine also stimulates the release of ADH and potentiates its action in promoting reabsorption of water; chemically related to tricyclic antidepressants; in addition to anticonvulsant effects, carbamazepine has anticholinergic, antineuralgic, antidiuretic, muscle relaxant and antiarrhythmic properties",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Slowly from the GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Carbamazepine and its active epoxide metabolite distribute into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates: 1.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 1.9 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 0.59-2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Carbamazepine: 75% to 90%, bound to alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein and nonspecific binding sites on albumin; protein binding may be decreased in newborns",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epoxide metabolite: 50% protein bound",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Induces liver enzymes to increase metabolism and shorten half-life over time; metabolized in the liver by cytochrome P450 3A4 to active epoxide metabolite; epoxide metabolite is metabolized by epoxide hydrolase to the trans-diol metabolite; ratio of serum epoxide to carbamazepine concentrations may be higher in patients receiving polytherapy (vs monotherapy) and in infants (vs older children); boys may have faster carbamazepine clearances and may, therefore, require higher mg/kg/day doses of carbamazepine compared to girls of similar age and weight",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability, oral: 75% to 85%; relative bioavailability of extended release tablet to suspension: 89%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carbamazepine:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial: 25-65 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Multiple dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children: 8-14 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adults: 12-17 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epoxide metabolite: 34 &plusmn; 9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Unpredictable, within 4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chronic administration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Suspension: 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet: 4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release tablet: 3-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 1% to 3% excreted unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1051486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/8/13446?source=see_link\">",
"      see \"Carbamazepine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol and grapefruit juice. May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. May cause dry mouth. Antiepileptic agents may increase the risk of suicidal thoughts and behavior; notify physician if you feel more depressed or have thoughts of suicide or self harm. Report fever, sore throat, infection, mouth ulcers, easy bruising, bleeding, loss of appetite, nausea, vomiting, yellow skin or eyes, changes in mentation or cognition, rash or skin irritations, worsening of seizure activity, or loss of seizure control to physician. Report the use of other medications, nonprescription medications, and herbal or natural products to your physician and pharmacist. The tablet coating of Tegretol&reg;-XR tablet is not absorbed and may appear in the stool. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1051497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Carbamazepine is not effective in absence, myoclonic, akinetic, or febrile seizures; exacerbation of certain seizure types have been seen after initiation of carbamazepine therapy in children with mixed seizure disorders",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Investigationally, loading doses of the suspension (10 mg/kg for children &lt;12 years of age and 8 mg/kg for children &gt;12 years) were given (via NG or ND tubes followed by 5-10 mL of water to flush through tube) to PICU patients with frequent seizures/status; 5 of 6 patients attained mean plasma concentrations of 4.3 mcg/mL and 7.3 mcg/mL at 1 and 2 hours postload; concurrent enteral feeding or ileus may delay absorption of loading dose (Miles, 1990)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Carbamazepine suspension may be administered rectally as maintenance doses, if oral therapy is not possible (",
"     <b>",
"      Note:",
"     </b>",
"     Rectally administered carbamazepine is not useful in status epilepticus due to its slow absorption); when using carbamazepine suspension rectally, administer the same total daily dose, but give in small, diluted, multiple doses; dilute the oral suspension with an equal volume of water; if defecation occurs within the first 2 hours, repeat the dose (Graves, 1987)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Extended release capsule (Cabatrol&reg;, Equetro&trade;) contain three different types of beads: Immediate-, extended-, and enteric-release; the combination of the ratio of bead types allows for twice daily dosing.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     A recent study (Relling, 2000) demonstrated that enzyme-inducing antiepileptic drugs (AEDs) (carbamazepine, phenobarbital, and phenytoin) increased systemic clearance of antileukemic drugs (teniposide and methotrexate) and were associated with a worse event-free survival, CNS relapse, and hematologic relapse, (ie, lower efficacy), in B-lineage ALL children receiving chemotherapy; the authors recommend using nonenzyme-inducing AEDs in patients receiving chemotherapy for ALL.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Individuals who possess a genetic susceptibility marker known as the",
"     <b>",
"      <i>",
"       HLA-B*1502",
"      </i>",
"     </b>",
"     allele have an increased risk of developing carbamazepine-associated Stevens-Johnson syndrome (SJS) and/or toxic epidermal necrolysis (TEN) compared to persons without this genotype. The presence of this genetic variant exists in up to 15% of people of Asian descent, varying from &lt;1% in Japanese and Koreans, to 2% to 4% of South Asians and Indians, to 10% to 15% of populations from China, Taiwan, Malaysia, and the Philippines. This variant is virtually absent in those of Caucasian, African-American, Hispanic, Native American, or European ancestry. Risk assessments have suggested that incidence of SJS/TEN in Asians could be ~60 cases/10,000 new users depending on the country of origin (a nearly 10-fold higher incidence than in predominantly Caucasian populations). Patients of Asian descent should be screened for the variant",
"     <b>",
"      <i>",
"       HLA-B*1502",
"      </i>",
"     </b>",
"     allele (genetic marker) prior to initiating therapy. Those who test positive should not be started on carbamazepine, unless the benefit exceeds the risks. Presence of the",
"     <b>",
"      <i>",
"       HLA-B*1502",
"      </i>",
"     </b>",
"     allele may signify greater risk of developing SJS/TEN with other antiepileptic agents for which this degree of dermatologic reactions has been documented.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10806347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Commercial oral suspension is available (20 mg/mL)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 40 mg/mL oral suspension may be made with tablets. Crush twenty 200 mg tablets in a mortar and reduce to a fine powder. Add small portions of Simple Syrup, NF and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     100 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add sufficient quantity of vehicle to make 100 mL. Label \"shake well\" and \"refrigerate\". Stable for 90 days.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Gilman JT, &ldquo;Carbamazepine Dosing for Pediatric Seizure Disorders: The Highs and Lows,&rdquo;",
"      <i>",
"       DICP",
"      </i>",
"      , 1991, 25(10):1109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/36/5706/abstract-text/1803802/pubmed\" id=\"1803802\" target=\"_blank\">",
"        1803802",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graves NM and Kriel RL, &ldquo;Rectal Administration of Antiepileptic Drugs in Children,&rdquo;",
"      <i>",
"       Pediatr Neurol",
"      </i>",
"      , 1987, 3(6):321-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/36/5706/abstract-text/3334021/pubmed\" id=\"3334021\" target=\"_blank\">",
"        3334021",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Korinthenberg R, Haug C, and Hannak D, &ldquo;The Metabolization of Carbamazepine to CBZ-10,11 Epoxide in Children From the Newborn Age to Adolescence,&rdquo;",
"      <i>",
"       Neuropediatrics",
"      </i>",
"      , 1994, 25(4):214-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/36/5706/abstract-text/7824094 /pubmed\" id=\"7824094 \" target=\"_blank\">",
"        7824094",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu H and Delgado MR, &ldquo;Influence of Sex, Age, Weight, and Carbamazepine Dose on Serum Concentrations, Concentration Ratios, and Level/Dose Ratios of Carbamazepine and Its Metabolites,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 1994, 16(5):469-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/36/5706/abstract-text/ 7846744 /pubmed\" id=\" 7846744 \" target=\"_blank\">",
"        7846744",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Matos ME, Burns MM, and Shannon MW, &ldquo;False-Positive Tricyclic Antidepressant Drug Screen Results Leading to the Diagnosis of Carbamazepine Intoxication,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 105(5), file://www.pediatrics.org/cgi/content/full/105/5/e66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/36/5706/abstract-text/10799630 /pubmed\" id=\"10799630 \" target=\"_blank\">",
"        10799630",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miles MV, Lawless ST, Tennison MB, et al, &ldquo;Rapid Loading of Critically Ill Patients With Carbamazepine Suspension,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(2):263-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/36/5706/abstract-text/237110/pubmed\" id=\"237110\" target=\"_blank\">",
"        237110",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Relling MV, Pui CH, Sandlund JT, et al, &ldquo;Adverse Effect of Anticonvulsants on Efficacy of Chemotherapy for Acute Lymphoblastic Leukaemia,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2000, 356(9226):285-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/36/5706/abstract-text/11071183/pubmed\" id=\"11071183\" target=\"_blank\">",
"        11071183",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13113 Version 52.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-425BDFC11D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_36_5706=[""].join("\n");
var outline_f5_36_5706=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708660\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145588\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145589\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051488\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051480\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145559\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145544\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10968527\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051493\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051484\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051492\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145644\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145642\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051496\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051479\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051478\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145630\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145553\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051499\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145555\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145571\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051487\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051491\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051477\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051495\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051486\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051497\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10806347\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13113\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13113|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=related_link\">",
"      Carbamazepine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/8/13446?source=related_link\">",
"      Carbamazepine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_36_5707="Complications of TBNA";
var content_f5_36_5707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complications of TBNA*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transient bacteremia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oozing of blood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inadvertent puncture of mediastinal structures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumothorax/pneumomediastinum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Damage to the working channel of the fiberoptic bronchoscope",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Rare if the proper technique is used and the appropriate precautions are taken.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Dasgupta, A, Mehta, AC, Clin Chest Med 1999; 20:39 andMinai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research-Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_36_5707=[""].join("\n");
var outline_f5_36_5707=null;
var title_f5_36_5708="Pharmacologic agents HTN";
var content_f5_36_5708=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=24\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=24\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pharmacologic agents to treat hypertension",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Pharmacologic agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Standard dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common side effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nifedipine",
"       </td>",
"       <td rowspan=\"4\">",
"        Calcium channel blocker",
"       </td>",
"       <td>",
"        10 to 20 mg three times daily, or extended release once daily",
"       </td>",
"       <td rowspan=\"4\">",
"        Hypotension, peripheral edema, headache, dizziness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amlodipine",
"       </td>",
"       <td>",
"        5 to 10 mg once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Felodipine",
"       </td>",
"       <td>",
"        2.5 to 10 mg once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nicardipine",
"       </td>",
"       <td>",
"        20 to 40 mg three times daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metoprolol",
"       </td>",
"       <td rowspan=\"2\">",
"        Beta blocker",
"       </td>",
"       <td>",
"        50 to 200 mg po twice daily, or extended release once daily",
"       </td>",
"       <td rowspan=\"2\">",
"        Hypotension, fatigue, dizziness, bradycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atenolol",
"       </td>",
"       <td>",
"        50 to 100 mg once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enalapril",
"       </td>",
"       <td rowspan=\"2\">",
"        ACE inhibitor",
"       </td>",
"       <td>",
"        5 to 40 mg once daily",
"       </td>",
"       <td rowspan=\"2\">",
"        Cough, dizziness, fatigue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lisinopril",
"       </td>",
"       <td>",
"        10 to 40 mg once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Losartan",
"       </td>",
"       <td>",
"        A2 receptor blocker",
"       </td>",
"       <td>",
"        25 to 100 mg once daily",
"       </td>",
"       <td rowspan=\"2\">",
"        Dizziness, headache, fatigue, URI symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valsartan",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        80 to 320 mg once daily",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_36_5708=[""].join("\n");
var outline_f5_36_5708=null;
var title_f5_36_5709="Causes of spinal cord infarct";
var content_f5_36_5709=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F57862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F57862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of spinal cord infarction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Aorta disease, procedures",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aortic surgery",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thoracic endovascular aortia repair (TEVAR)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aortic dissection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Traumatic rupture of the aorta",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aortic thrombosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aortic aneurysm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Coarctation of the aorta",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aortography",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Systemic hypoperfusion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cardiac arrest",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Systemic bleeding",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Cardiogenic embolism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Atrial myxoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mitral valve disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Patent foramen ovale",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bacterial endocarditis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cardiac catheterization",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Vasculitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Systemic lupus erythematosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Polyarteritis nodosa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Behcet syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Giant cell arteritis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bacterial meningitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Syphilis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mucormycosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hematologic disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypercoagualable conditions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sickle cell anemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Non-aortic surgeries",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Spine disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Spine surgery",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cervical spondylosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fibrocartilagenous embolism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Epidural steroid injections",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Miscellaneous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cocaine abuse",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vertebral artery dissection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Spinal vascular malformation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Decompression sickness",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_36_5709=[""].join("\n");
var outline_f5_36_5709=null;
var title_f5_36_5710="ACCESS criteria sarcoid A";
var content_f5_36_5710=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65081%7EPULM%2F72769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65081%7EPULM%2F72769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACCESS study criteria for organ involvement in patients with biopsy-confirmed sarcoidosis-I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Organ",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definite",
"       </td>",
"       <td class=\"subtitle1\">",
"        Probable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Lungs",
"       </td>",
"       <td class=\"sublist1_start\">",
"        1. Chest roentgenogram with one or more of the following:",
"       </td>",
"       <td>",
"        1. Lymphocytic alveolitis by bronchoalveolar lavage (BAL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bilateral hilar adenopathy",
"       </td>",
"       <td>",
"        2. Any pulmonary infiltrates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diffuse infiltrates",
"       </td>",
"       <td rowspan=\"3\">",
"        3. Isolated reduced diffusing capacity for carbon monoxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Upper lobe fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Restriction on pulmonary function tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Skin",
"       </td>",
"       <td>",
"        1. Lupus pernio",
"       </td>",
"       <td>",
"        1. Macular/papular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Annular lesion",
"       </td>",
"       <td rowspan=\"2\">",
"        2. New nodules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Erythema nodosum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Eyes",
"       </td>",
"       <td>",
"        1. Lacrimal gland swelling",
"       </td>",
"       <td rowspan=\"3\">",
"        1. Blindness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Uveitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Optic neuritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Neurologic",
"       </td>",
"       <td>",
"        1. Positive magnetic resonanceimaging (MRI) with uptake in meninges or brainstem",
"       </td>",
"       <td>",
"        1. Other abnormalities on magnetic resonance imaging (MRI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Cerebrospinal fluid with increased lymphocytes and/or protein",
"       </td>",
"       <td>",
"        2. Unexplained neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Diabetes insipidus",
"       </td>",
"       <td rowspan=\"4\">",
"        3. Positive electromyogram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Bell's palsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Cranial nerve dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Peripheral nerve biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <p>",
"         Hypercalcemia",
"        </p>",
"        <p>",
"         Hypercalciuria",
"        </p>",
"        <p>",
"         Nephrolithiasis",
"        </p>",
"       </td>",
"       <td rowspan=\"2\">",
"        1. Increased serum calcium with no other cause",
"       </td>",
"       <td>",
"        1. Increased urine calcium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Nephrolithiasis analysis showing calcium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Cardiac",
"       </td>",
"       <td>",
"        1. Treatment responsive cardiomyopathy",
"       </td>",
"       <td class=\"sublist1_start\">",
"        1. No other cardiac problem and either:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        2. Electrocardiogram showing intraventricular conduction defect or nodal block",
"       </td>",
"       <td class=\"sublist1\">",
"        Ventricular arrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        3. Positive gallium scan of heart",
"       </td>",
"       <td>",
"        2. Positive thallium scan",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Judson, MA, RP Baughman, AS. Teirstein, ML Terrin, and H Yeager, Jr. 1999. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases 16:75-86. Copyright &copy; 1999 Sarcoidosis, Vasculitis, and Diffuse Lung Diseases.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACCESS study criteria for organ involvement in patients with biopsy-confirmed sarcoidosis - II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Organ",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definite",
"       </td>",
"       <td class=\"subtitle1\">",
"        Probable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Nonthoracic lymph node",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        1. New palpable node above waist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Lymph node &gt;2 cm by computed tomographic (CT) scan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Parotid/salivary glands",
"       </td>",
"       <td>",
"        1. Symmetrical parotitis with syndrome of mumps",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Positive gallium scan (\"Panda sign\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal",
"       </td>",
"       <td>",
"        1. Treatment responsive renal failure",
"       </td>",
"       <td>",
"        1. Steroid responsive renal failure in patient with diabetes and/or hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Liver",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        1. Liver function tests &gt; three times normal",
"       </td>",
"       <td>",
"        1. Compatible computed tomographic (CT) scan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Elevated alkaline phosphatase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Spleen",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"1\" rowspan=\"4\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist1_start\">",
"        1. Enlargement by:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Exam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"1\">",
"        Computed tomographic (CT) scan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Radioisotope scan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Bone marrow",
"       </td>",
"       <td>",
"        1. Unexplained anemia",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Leukopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Thrombocytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone/joints",
"       </td>",
"       <td>",
"        1. Cystic changes on hand or feet phalanges",
"       </td>",
"       <td>",
"        1. Asymmetric painful clubbing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ears/Nose/Throat",
"       </td>",
"       <td colspan=\"1\">",
"        1. Unexplained hoarseness with exam consistent with granulomatous involvement",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Muscles",
"       </td>",
"       <td>",
"        1. Increased creatine phosphokinase (CK) aldolase which decreases with treatment",
"       </td>",
"       <td>",
"        1. Increased creatine, phosphokinase (CK)/aldolase",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Judson, MA, RP Baughman, AS. Teirstein, ML Terrin, and H Yeager, Jr. 1999. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases 16:75-86. Copyright &copy; 1999 Sarcoidosis, Vasculitis, and Diffuse Lung Diseases.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_36_5710=[""].join("\n");
var outline_f5_36_5710=null;
var title_f5_36_5711="Preseptal and orbital cellulitis studies";
var content_f5_36_5711=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical manifestations of preseptal and orbital cellulitis studies on admission",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" rowspan=\"4\">",
"        &nbsp;",
"        <br/>",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"10\">",
"        Study: Study design, patient population",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Nageswaran, et al",
"        <sup>",
"         [1]",
"        </sup>",
"        :",
"        <br/>",
"        Retrospective, children",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Botting, et al",
"        <sup>",
"         [2]",
"        </sup>",
"        :",
"        <br/>",
"        Retrospective, children",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Chaudhry, et al",
"        <sup>",
"         [3]",
"        </sup>",
"        :",
"        <br/>",
"        Retrospective",
"        <sup>",
"         &bull;",
"        </sup>",
"        , children and adults",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Sobol, et al",
"        <sup>",
"         [4]",
"        </sup>",
"        :",
"        <br/>",
"        Retrospective, children",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Seltz, et al",
"        <sup>",
"         [5]",
"        </sup>",
"        :",
"        <br/>",
"        Retrospective, children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\" colspan=\"2\">",
"        Type of cellulitis",
"       </td>",
"       <td class=\"subtitle3\" colspan=\"2\">",
"        Type of cellulitis",
"       </td>",
"       <td class=\"subtitle3\" colspan=\"2\">",
"        Type of cellulitis",
"       </td>",
"       <td class=\"subtitle3\" colspan=\"2\">",
"        Type of cellulitis",
"       </td>",
"       <td class=\"subtitle3\" colspan=\"2\">",
"        Type of cellulitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preseptal",
"       </td>",
"       <td>",
"        Orbital (n = 41)",
"       </td>",
"       <td>",
"        Preseptal (n = 227)",
"       </td>",
"       <td>",
"        Orbital (n = 35)",
"       </td>",
"       <td>",
"        Preseptal (n = 104)",
"       </td>",
"       <td>",
"        Orbital",
"       </td>",
"       <td>",
"        Preseptal (n = 101)",
"       </td>",
"       <td>",
"        Orbital (n = 26)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Preseptal",
"       </td>",
"       <td>",
"        Orbital (n = 94)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Age (yrs)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        7.5 (range 0-16)",
"       </td>",
"       <td>",
"        3.9",
"       </td>",
"       <td>",
"        7.5",
"       </td>",
"       <td>",
"        19 (range 0-75)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        3.8 (range 0-16)",
"       </td>",
"       <td>",
"        6.4 (range 0-13)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        6 (range 0-18)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of trauma*",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Excluded",
"       </td>",
"       <td>",
"        89 (39)",
"       </td>",
"       <td>",
"        4 (11)",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Excluded",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eye pain and/or tenderness",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        64 (62)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eyelid swelling +/- erythema",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        104 (100)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proptosis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        25 (61)",
"       </td>",
"       <td>",
"        2 (0.9)",
"       </td>",
"       <td>",
"        33 (94)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1 (1)",
"       </td>",
"       <td>",
"        20 (77)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        36 (38)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ophthalmoplegia",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        19 (46)",
"       </td>",
"       <td>",
"        1 (0.4)",
"       </td>",
"       <td>",
"        4 (11)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1 (1)",
"       </td>",
"       <td>",
"        20 (77)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        45 (48)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diplopia",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2 (0.9)",
"       </td>",
"       <td>",
"        19 (54)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vision impaired",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1 (3)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        3 (3)",
"       </td>",
"       <td>",
"        3 (11)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        11 (12)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No ophthalmologic signs (proptosis, ophthalmoplegia, visual loss)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        11 (27)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chemosis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        10 (11)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        27 (66)",
"       </td>",
"       <td>",
"        106 (47)",
"       </td>",
"       <td>",
"        33 (94)",
"       </td>",
"       <td>",
"        Children 52 percent; adults 10 percent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        59 (59)",
"       </td>",
"       <td>",
"        18 (69)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        63 (67)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        White blood cell count &gt;15,000",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        19 (46)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Sinusitis",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        21 (9)",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        32 (91)",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ethmoid sinusitis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        40 (98)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        30 (86)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        22 (86)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        87 (93)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Maxillary sinusitis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        29 (71)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        21 (60)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        22 (86)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        84 (89)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subperiosteal abscess",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        24 (59)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        12 (34)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &Delta;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        44 (47)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orbital abscess",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        10 (24)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2 (6)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        8 (8)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgical procedure",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        29 (71)",
"       </td>",
"       <td>",
"        11 (5)",
"       </td>",
"       <td>",
"        8 (23)",
"       </td>",
"       <td>",
"        52 (50)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        6 (23)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Results are reported as number of patients with a given finding (percent).",
"    <div class=\"footnotes\">",
"     * Eg, insect bites, scratches.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      This study involved patients referred to a tertiary care hospital in Saudi Arabia. 38.5 percent of patients were &gt;16 years of age. Many had acute dacryocystitis, trauma, or recent surgery, which is probably why such a large proportion of patients underwent surgical procedures.",
"      <br>",
"       &Delta; In this study, 12 cases of children with subperiosteal abscess were evaluated separately; these cases are not shown in the table, but the findings were similar to those with simple orbital cellulitis. Of patients with orbital cellulitis or subperiosteal abscess, 12 of 38 (32 percent) had a subperiosteal abscess; 66 percent of patients with subperiosteal abscess underwent surgery.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        The mean age is reported for all studies except for Seltz et al",
"        <sup>",
"         [5]",
"        </sup>",
"        ; this study reported the median age.",
"        <br>",
"         &sect; The ethmoid and maxillary sinuses were involved most commonly, but some patients had frontal sinusitis and/or sphenoid sinusitis; many patients had involvement of multiple sinuses.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Nageswaran S, Woods CR, Benjamin DK Jr, et al. Orbital cellulitis in children. Pediatr Infect Dis J 2006; 25:695.",
"       </li>",
"       <li>",
"        Botting AM, McIntosh D, Mahadevan M. Paediatric pre- and post-septal peri-orbital infections are different diseases - A retrospective review of 262 cases. Int J Pediatr Otorhinolaryngol 2008; 72:377.",
"       </li>",
"       <li>",
"        Chaudhry IA, Shamsi FA, Elzaridi E, et al. Inpatient preseptal cellulitis: experience from a tertiary eye care centre. Br J Ophthalmol 2008; 92:1337.",
"       </li>",
"       <li>",
"        Sobol SE, Marchand J, Tewfik TL, et al. Orbital complications of sinusitis in children. J Otolaryngol 2002; 31:131.",
"       </li>",
"       <li>",
"        Seltz LB, Smith J, Durairaj VD, et al. Microbiology and antibiotic management of orbital cellulitis. Pediatrics 2011; 127:e566.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_36_5711=[""].join("\n");
var outline_f5_36_5711=null;
              